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The synthesis of the first series of a new class of nucleoside phosphonate analogues is described. 
Addition of a carboxyl group at the alpha position of carbocyclic nucleoside phosphonate analogues 
leads to a novel class of potent HIV reverse transcriptase (RT) inhibitors, α-carboxy nucleoside 
phosphonates (α-CNPs). Key steps in the synthesis of the compounds are Rh-catalyzed O–H insertion 
and Pd-catalyzed allylation reactions. The final products are markedly inhibitory against HIV RT and 
do not require phosphorylation to exhibit anti-RT activity, which indicates that the α-
carboxyphosphonate function is efficiently recognized by HIV RT as a triphosphate entity, an 




The human immunodeficiency virus (HIV) was first identified as the causative agent of acquired 
immunodeficiency syndrome (AIDS) in 1983.1 At the close of 2012 there were an estimated 35 million 
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people living with the retrovirus worldwide, with approximately 2.3 million people newly infected in 
2012 alone. 2  The introduction of HAART (highly active antiretroviral therapy) in 1996 has 
transformed HIV from a lethal infection to a manageable chronic condition with considerable declines 
in HIV-associated morbidity and mortality.3- 6 However, as a result of the high genetic variability of 
the retrovirus, resistance to current drug therapies is a major problem and in addition to HIV there are 
numerous other chronic viral infections such as hepatitis B and C.7 Approximately 1 in 12 persons 
worldwide, or a total of some 500 million people, are living with chronic viral hepatitis.2 In light of 
this, a vast amount of time and effort has been invested in the design and synthesis of antiviral agents, 
most notably nucleoside analogues, and the discovery of new, more efficient antiviral agents is still 
imperative.  
Nucleoside reverse transcriptase inhibitors (NRTIs) were the first class of anti-HIV drugs approved 
and, despite the discovery of numerous other classes of anti-HIV agents (e.g. nucleotide reverse 
transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, integrase 
inhibitors, cell entry inhibitors and co-receptor inhibitors), they have continued to play a pivotal role in 
HIV treatment.8 NRTIs disrupt viral replication through two distinct modes; competitive inhibition of 
HIV RT with respect to the dNTP substrate, and DNA chain termination.9,10 However, in order to do 
this, these compounds must be first converted via a series of host cell kinases to their active 
triphosphate form.10- 12  The triphosphorylated drug molecules then compete with the natural 
nucleotides to be accepted into the growing DNA chain and, upon incorporation, DNA chain 
elongation is terminated since the NRTIs lack the 3′-OH group of endogenous nucleosides.10 Poor cell 
membrane permeability coupled with the labile nature of the phosphate bond precludes the direct 
delivery of the active triphosphorylated form of the drug into the virus-infected cell. 13  This 
predicament was partially overcome by the discovery of the phosphonate as a stable isostere for the 
phosphate bond, 14 , 15  and by the use of phosphoramidate, CycloSal or alkoxyalkyl prodrug 
technology16- 19  
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The discovery of (S)-HMPA as a broad spectrum antiviral agent15 swiftly led to the development of a 
new class of anti(retro)viral agents: the nucleotide reverse transcriptase inhibitors (NtRTIs). Tenofovir 
(PMPA)20 is the only nucleotide reverse transcriptase inhibitor currently approved by the FDA for the 
treatment of HIV and HBV. It is marketed as the prodrug tenofovir disoproxil fumarate (TDF) which 
is hydrolyzed in vivo to tenofovir.8,10 The presence of the phosphonate group enables the compound to 
bypass the initial phosphorylation step, which is often rate-limiting, and just two more 
phosphorylations are required to furnish the anti(retro)virally-active tenofovir-diphosphate.8 
Beside the N(t)RTIs, two more compound classes have been described as potent inhibitors of HIV-1: 
non-nucleoside RT inhibitors (NNRTI),21 and nucleoside-competing reverse transcriptase inhibitors 
(NcRTI), such as INDOPY-1.22 Both represent agents with a structure different from nucleosides, and 
do not need metabolic activation (phosphorylation) to interact with their RT target. 
Carbocyclic nucleosides are an important subclass of NRTIs where the oxygen of the furanose ring has 
been replaced by a methylene group.23-25 This substitution renders these compounds stable to cleavage 
by intracellular phosphorylases and hydrolases as they lack the labile glycosidic bond of natural 
nucleosides. Carbocyclic nucleosides also exhibit increased lipophilicity relative to conventional 
nucleosides leading to increased in vivo half-life, oral uptake efficiency and cell membrane 
penetration.24 Naturally-occurring compounds of this type include aristeromycin 1 and neplanocin A 
226 which possess potent antitumor and antiviral activities. Synthetic carbocyclic derivatives include 
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The phosphononucleoside 529 and the carbocyclic phosphononucleoside 630 possess significant anti-
HIV activity, and the diphosphorylated carbocyclic phosphononucleoside derivative 7 strongly inhibits 
HIV-RT.14 In addition to this, the anti(retro)viral properties of phosphonoformic acid (PFA) 8 and 
phosphonoacetic acid (PAA) 9 were established almost 3 decades ago. 31  McKenna et al. later 
synthesized a range of halogen- and methyl-substituted derivatives of PAA, a number of which were 
found to possess potent anti(retro)viral activity. Interestingly, the carbonyl derivative 10 was 
significantly more active than 9.32  The attachment of PAA and PFA by ester and amide linkages to the 
5′-O and N- positions of 3TC has been reported, but the resulting derivatives were less active against 





In general phosphononucleoside research involves compounds bearing a simple CH2PO(OH)2 
substituent. However, there have been some reports of derivatives bearing substituents geminal to the 
phosphonic acid moiety.34- 39 Vederas et al. reported the synthesis of nucleoside dicarboxylates as 
potential nucleoside diphosphate isosteres. 40  Recently Janeba has described acyclic nucleoside 
phosphonates incorporating an additional remote carboxylic acid function, but these compounds did 
not exhibit any anti(retro)viral activity.41 Gilbert and co-workers described the synthesis of citrate 
derivatives of nucleosides as potential mimics of nucleoside triphosphates.42,43 The compounds were 
found to be inactive, indicating that the citrate moiety is not a good replacement for the phosphate 
group(s). 
We have previously examined the O–H insertion reaction of diazophosphonoacetates with nucleoside 
derivatives as a route to obtain functionalized phosphonate analogues.44,45 The α-carboxyphosphonate 
function was designed as a novel structural motif, which we originally considered as a potential 
diphosphate (or monophosphate) mimic, to provide a new class of antiviral agents. Although the 
compounds in the original nucleoside series were found to be biologically inactive, we envisaged that 
related carbocyclic compounds 11a-f would be much more sterically similar to the natural nucleoside 
substrates, and therefore more likely to inhibit HIV RT, either in phosphorylated or non-
phosphorylated form (Figure 1). We were also interested in compounds such as the unsaturated 






11a Base = thymine
11b Base = uracil
11c Base = cytosine
11d Base = adenine
11e Base = guanine

















isosteric not isosteric  
 
Figure 1. Structural comparison of carbocyclic-CNP, nucleoside monophosphonate, and 
nucleoside carboxymethylphosphonate 
 
The objective of this study was to synthesise a series of α–carboxy nucleoside phosphonates (α-CNPs) 
11a-f, 12 and 13 incorporating a carbocyclic framework for evaluation as potential HIV-1 RT 
inhibitors. 
 
2. Results and discussion 
Two strategies can be envisaged for the approach to the desired compounds 11, viz. O–H insertion on 
the cyclopentanol core prior to introduction of the nucleoside base, or alternatively insertion of the 
base initially followed by O–H insertion (Scheme 1). For this series of compounds we elected to use 
the former approach; while the latter approach is feasible, that route requires extra synthetic steps due 
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to the need for protecting groups to block competing reactions at the nucleoside base, or poisoning of 
the catalyst by the base. 
 











2.1. O–H Insertion reactions 
We have recently reported that rhodium-catalyzed O–H insertion provides a mild and neutral way of 
attaching the phosphonate group to suitably protected nucleosides.44,45 For the preparation of the 
carbocyclic nucleoside phosphonate analogues, the key O–H insertion reactions were carried out using 
the acetoxy alcohol 14 and trimethyl phosphonodiazoacetate in the presence of rhodium(II) acetate or 
copper(II) triflate, to afford the desired product 15 (Scheme 2). During the early stages of the project, 
reactions were also carried out with triethyl phosphonodiazoacetate; while these reactions proceeded 
smoothly to afford 16 in good yield, the triethyl derivatives were set aside in favor of the trimethyl 
derivatives due to ease of deprotection later in the synthetic sequence.  
 
Scheme 2. O–H insertion reaction.a 
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HO OAc O OAc(RO)2OP
CO2R
14 15 R = Me
16 R = Et
80-90% yield
69% yield  
aConditions: (RO)2OPC(N2)CO2R, Rh2(OAc)4 or Cu(OTf)2, C6H6, 80 °C 
 
The O–H insertion reactions were essentially complete within 4–5 h at reflux in benzene, however, 
since it was determined that a longer reaction time did not deleteriously impact on the yield, the 
reactions were generally heated overnight (17–24 h). The isolated yields were typically high; 70–80% 
with Cu(OTf)2, and 80–90% with Rh2(OAc)4. The product 15 was formed as an equimolar mixture of 
diastereomers, readily identified spectroscopically from the characteristic signals in the 1H and 13C 
NMR spectra for the CH adjacent to the phosphorus. Although separation of the diastereomers can be 
achieved to an extent by chromatography, complete separation of the diastereomers was not attempted. 
 
2.2. Base insertion reactions 
The introduction of the nucleobases onto the allylic acetate 15 was next undertaken. Tsuji-Trost-type 
palladium(0)-catalyzed allylic substitution offers a mild method for the attachment of the nucleobases 
and has the added advantage of regio- and stereoselectivity.46- 49 We investigated the use of different 
palladium catalysts including Pd(PPh3)4, Pd(dba) or Pd2(dba3)·CHCl3 with various phosphines, the use 
of Cs2CO3 and Na2CO3 at various concentrations, and the use of different solvents at various 
temperatures and reaction times, and the use of microwave irradiation (Scheme 3). The reactions were 
found to be somewhat variable, sometimes affording moderate to good yields of the desired products 
17, but sometimes failing inexplicably. The most reliable conditions we found involved the use of 
Pd(dba)2, dppb and Na2CO3 in aqueous acetonitrile at 55 °C overnight, or under microwave irradiation 
for 45–60 min. The reactions carried out in the microwave have the added advantage of short reaction 
times. We prepared compounds 17a-f, incorporating thymine, uracil, cytosine, adenine, 2-amino-6-
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chloropurine and 5-fluorouracil in this way. The crude adenine and 2-amino-6-chloropurine derivatives 
were isolated as mixtures of N-7 and N-9 isomers but after purification the N-9 isomer was obtained in 
pure form. 
 























































aConditions: (a) Base, Pd(PPh3)4, Na2CO3, aq. MeCN, 55 °C; (b) Base, Pd(dba)2, dppb, Na2CO3, aq. 
MeCN, 55 °C; (c) Base, Pd(dba)2, dppb, Na2CO3, aq. MeCN, microwave 55 °C; (d) H2, Pd/C, MeOH 
 
2.3. Characterisation and Stability of the Phosphononucleosides 
Although we did not attempt full separation of the diastereomers of 17, chromatography of these 
compounds often led to the isolation of fractions with different diastereomeric ratios, and we generally 
observed that the diastereomeric ratio of the bulk crude product of the base insertion reaction was the 
same as that of the starting allylic acetate. As is the case for the products of the O-H insertion, the 
majority of 1H and 13C NMR signals are quite well-distinguished for the two individual diastereomers. 
The trimethyl derivatives 17a and b can be kept at room temperature neat or in solution for extended 
periods without any detectable decomposition, while derivatives 17c-e were found to be more labile. In 
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particular the trimethyl cytosine derivative 17c was found to be labile in solution leading to a complex 
mixture of unidentifiable products. 
 
2.4. Hydrogenation reactions 
Compounds 17a-f were hydrogenated at 20–50 psi over palladium on carbon catalyst (Scheme 3) 
affording the saturated derivatives 18a-f. For the thymine and uracil derivatives 17a-b the reaction is 
complete within 1.5 h at 20–30 psi and was essentially quantitative, although these compounds were 
isolated in 86-92% yields following chromatography. These reactions could also be carried out over 
24–48 h at atmospheric pressure using a hydrogen balloon. The cytosine derivative 17c required longer 
reaction times or increased catalyst loading and was isolated in lower yield (80%) than the thymine 
and uracil derivatives. The adenine derivative 17d also required more forcing conditions. Complete 
hydrogenation of the 2-amino-6-chloropurine derivative 17e proved more challenging, and a fully 
hydrogenated sample was not obtained.  
 
2.5. Deprotection 
The derivatives 18a-d and 18f were deprotected using essentially the same procedure we applied for 
the deprotection of the related series of nucleoside derivatives.44,45 Thus, the trimethyl derivatives were 
treated with excess TMSBr, followed by addition of water and then treatment with aqueous NaOH 
(1M, 10 equiv) at room temperature or at 50 °C. The reaction with TMSBr could also be carried out in 
the microwave, leading to cleavage of the phosphonate esters after 10–15 minutes irradiation at 50 °C 
(Scheme 4). In the case of the adenine derivative, invariably a small amount of the carboxylic methyl 
ester remained intact (~5%) even after prolonged stirring with aqueous NaOH at 50 °C (3 days). It is 
possible that heating at a higher temperature could drive the reaction to completion.  
 






















yield over two steps
isolated as ammonium salts
18 19
 
aConditions: (a) TMSBr, CH2Cl2, rt 18 h or MeCN, microwave 50 °C, 15 min; (b) aq. MeOH, or H2O, 
30 min; (c) concentration in vacuo; (d) aq. NaOH, rt or 50 °C; (e) charcoal chromatography44,45  
 
Exposure of the unsaturated trimethyl ester 17a to TMSBr resulted in complete degradation of the 
starting material. Fortunately, when the reaction of 17a or 17f with TMSBr was carried out in the 
presence of 2,6-lutidine,50 then the intermediate phosphonic acid-carboxylic ester 20 could be isolated 
cleanly. Saponification of the carboxylic ester was then straightforward, giving the fully deprotected 
unsaturated thymine and 5-fluorouracil derivatives 12a and 12f (Scheme 5). 
 













12f  5-f luorouracil
61%
58%
yield over two steps
isolated as ammonium salts
17 20
 
aConditions: (a) TMSBr, lutidine, MeCN microwave 50 °C; (b) H2O, 30 min; (c) concentration in 
vacuo; (d) aq. NaOH, 50 °C; (e) charcoal chromatography44,45 
 
The intermediate partially-deprotected compounds 19a-d could be isolated following treatment with 
TMSBr (5 equiv.) and were found to be stable for extended periods of time when stored at neutral pH 
or as their ammonium salts. To prevent the HBr generated in the reaction from cleaving the carboxylic 
ester it was important to adjust the pH of the reaction mixture to 7 with 10% sodium hydroxide before 
the water was removed at a temperature below 30 °C through co-evaporation with acetonitrile. 
Concentration in vacuo at a higher temperature resulted in partial hydrolysis of the carboxylic ester 
(Scheme 6).  
 



















aConditions: (a) TMSBr, CH2Cl2, rt 18 h; (b) H2O, 30 min; (c) NaOH to pH 7 
 
The novel phosphononucleosides 11a-d and 11f were purified using charcoal chromatography.44,45 The 
fully deprotected compounds were not stable in acidic solutions, therefore in each case the crude 
material was adjusted to pH 1–2.5 immediately prior to adsorption onto the charcoal column. After 
eluting with ammonia, the ammonium salts of 11a-d and 11f were isolated in 57–71% yield, as clear 
or pale pink gums. Following lyophilisation, these salts were isolated as fine white solids that can be 
stored for over a year at room temperature without noticeable decomposition. The partially hydrolyzed 
derivatives 19a-d, with the intact carboxylic ester, could also be purified by charcoal column 
chromatography, eluting with 10:10:3 ethanol/water/ammonia hydroxide. 
 
2.6. Synthesis of the Enantio-enriched Series of Phosphononucleosides  
Having prepared the racemic phosphononucleosides 11a-d, the synthesis of these derivatives in 
enantiopure form (“natural” and “unnatural” enantiomers) was next undertaken. The 
phosphononucleosides (+)-11a-d and (−)-11a-d were isolated in similar yields in each synthetic step to 
those described for the corresponding racemic derivatives 11a-d. Wherever possible, specific rotations 
were recorded at each step, and development of HPLC conditions on a chiral stationary phase was 
undertaken for the unsaturated and saturated phosphononucleosides 17a-d and 18a-d. The enantiomers 
of the intermediates 17b and 18b were easily separated by using a Chiralcel® OJ-H column, with all 
four peaks clearly resolved. Separation of the enantiomers of the saturated thymine derivative 18a was 
successful to a degree using a Chiralpak® AS-H column, although complete resolution of all four peaks 
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was not achieved. Tracking of the enantiopurities of a number of intermediates in the synthesis of the 
enantio-enriched thymine and uracil derivatives 11a and 11b, by chiral HPLC and specific rotation, 
shows that the enantiopurity of the saturated derivatives 18a and 18b are the same as that of the 
starting acetoxy alcohol 14 in each case, thereby confirming that the stereochemical integrity of the 
precursor 14 is retained throughout the synthetic sequence. While the D-series was prepared starting 
from 14 with ≥98% enantiopurity in all cases, we prepared the L-series using several batches of 14 
with varying degrees of enantiopurity (ee 30–99%). 
 
2.7. Structural modifications 
The non-phosphonate derivative 
In order to determine whether the phosphonate group is necessary for biological activity we prepared 
the carboxymethyl derivative 23 (Scheme 7). Rhodium-catalyzed O–H insertion of the acetoxy alcohol 
14 with benzyl diazoacetate afforded the necessary allylic acetate 21 which was converted into the 
thymine derivative 22 by reaction with thymine in the presence of Pd(dba)2/dppb and sodium 
carbonate in aqueous acetonitrile. Hydrogenation of 22 resulted in simultaneous cleavage of the benzyl 
ester and reduction of the double bond to give the desired non-phosphonate free acid derivative 23. 
The yields for this sequence were not optimized. 
 
Scheme 7. Synthesis of non-phosphonate derivative 23.a 

















aConditions: (a) N2CHCO2Bn, Rh2(OAc)4, C6H6 80 °C; (b) thymine, Pd(PPh3)4, Na2CO3, aq. MeCN 50 
°C MW; (c) H2, Pd/C 1 atm, MeOH. 
 
Oxygenated derivatives 
Attempts to use the Upjohn conditions to dihydroxylate the unsaturated derivative 17a led to low 
conversion or no reaction. Stoichiometric reaction with OsO4 did result in the formation of the desired 
dihydroxylated material 24 (Scheme 8). We assume that the dihydroxylation had taken place on the 
face of the double bond opposite to the base and carboxyphosphonate functions. The full deprotection 
to afford the diol-substituted compound 13 was achieved using the normal procedure, using TMSBr 
followed by saponification. 
While attempted epoxidation of 17a with MCPBA resulted only in recovery of the unsaturated 
substrate, reaction with H2O2 in the presence of benzonitrile51 did proceed to afford the epoxide 25 
(Scheme 8), but a very large excess of the reagent (25 equiv.) was required and monitoring of the 
reaction was complicated by the fact that the starting material and product co-eluted on TLC. The co-
elution also made separation difficult on a preparative scale, but the desired material 25 was isolated 
cleanly, albeit in low yield (25%). The epoxide was partially deprotected using TMSBr in the presence 
of lutidine to afford the methyl ester 26, however a pure sample was not obtained, and full 
deprotection was not achieved for this compound due to limitations of scale. 
 










































aConditions: (a) aq. OsO4, THF, 24 h rt; (b) TMSBr, MeCN, 50 °C MW, 10 min; (c) aq. LiOH, 60 °C 
3.5 h; (d) charcoal chromatography;44,45 (e) 30% aq. H2O2, PhCN, K2CO3, MeOH; (f) TMSBr, lutidine, 
MeCN, 50 °C MW, 10 min. 
 
2.8. Biochemical and Biological Evaluation 
The novel compounds 11a-d, 11f, (+)-11a-d, (−)-11a-d, 12a, 12f, 13, 18a, (+)-18a, (−)-18a, and 23 
were evaluated for their inhibitory activity against a broad range of DNA and RNA viruses and were 
found to be inactive at 100 μg/mL. The following viruses were included in this study: herpes simplex 
virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2), vaccinia virus, respiratory syncytial virus 
(RSV), vesicular stomatitis virus (VSV), Coxsackie B4, Parainfluenza 3, Influenza virus A, influenza 
virus B, Reovirus-1, Sindbis, Reovirus-1, Punta Toro, human immunodeficiency virus type 1 (HIV-1) 
and human immunodeficiency virus type 2 (HIV-2). They were not cytostatic/cytotoxic at the highest 
concentration used (100 µg/ml). These results might be explained by the charged nature of the 




Therefore, the compounds were further investigated using a cell-free HIV-1-RT assay. A number of 
the compounds were found to strongly inhibit HIV-1 RT (Table 1). Most notably, when examined as 
potential inhibitors of HIV-1-RT-catalyzed incorporation of [3H]dTTP in a poly rA/oligo dT 
template/primer, the (−) enantiomers of 11a and 11b, corresponding to the “unnatural” L-thymine and 
L-uracil nucleosides, displayed potent inhibitory activity, and were considerably more active than their 
(+)-11a and (+)-11b counterparts; greater antiviral activity of the L-enantiomer in nucleoside 
derivatives has been described before, examples include 3TC and FTC.54 The thymine derivative 11a 
and uracil derivative 11b showed no marked, if any, inhibition of the incorporation of [3H]dCTP in 
poly rI/oligo dC and of [3H]dATP in poly rU/oligo dU at 500 μM, pointing to a specific competition 
with [3H]dTTP but not with [3H]dCTP or [3H]dATP. Likewise, the cytosine derivative (−)-11c 
displayed strong inhibition in the [3H]dCTP-poly rI/dC system but not in the other systems. Finally, 
the adenine derivative 11d proved to be a potent inhibitor of HIV-1 RT in the [3H]dATP-poly rU/dA 
system but not in the other systems. In all cases, the (−)-enantiomer was by far superior to the (+)-
enantiomer, pointing to a high degree of enantiospecificity of these compounds for HIV-1 RT 
inhibition. The inactivity of compound 23 indicates that both the carboxyl and phosphonate functions 
are required for HIV-1 RT inhibition. 
 
Table 1. Inhibitory activity of the compounds against HIV-1 reverse transcriptase using different 
template/primers and natural dNTP substrates 








11a 0.41 ± 0.08 >500 293 ± 22 
(+)-11a 35 ± 5 >500 96 ± 63 
(−)-11a 0.41 ± 0.00 >500 158 ± 150 
11b 3.7 ± 2 >500 139 ± 156 
(+)-11b 113 ± 105 >500 159 ± 60 
(−)-11b 3.1 ± 1.7 >500 222 ± 77 
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11c 219 ± 123 4.5 ± 1.1 102 ± 5.7 
(+)-11c 22.2 ± 17.7 382 ± 122 51 ± 3 
(−)-11c 171 ± 22 4.2 ± 0.3 48 ± 0 
11d ≥500 >500 0.26 ± 0.05 
(+)-11d 464 ± 3 >500 32 ± 8 
(−)-11d >500 >500 0.19 ± 0.11 
11f 3.8 ± 0.0 - - 
12a 1.9 ± 1.1 - - 
12f 2.4 ± 0.8 - - 
13 468 - - 
18a >500 146 ±20 >500 
(+)-18a >500 >500 >500 
(−)-18a >500 >500 >500 
23 >700 - - 
AZT-TP 0.069 ± 0.032 - - 
ddCTP - 11.1 ± 0.9 - 
ddATP - - 1.16 ± 0.19 
 
aFifty percent inhibitory concentration, or compound concentration required to inhibit HIV-RT-catalyzed incorporation of 
[3H]dNTP in the homopolymeric template/primer. Data are the mean ± SD of at least 3 to 4 independent experiments. 
“ - ”: Not performed. 
 
 
McClure et al. compared the inhibitory activity of 6 licensed NRTIs using a cell-free HIV-RT assay.55 
Although not a direct comparison, the results reported by McClure indicate that the most active 
phosphononucleoside derivatives (−)-11a (IC50 = 0.41 μM) and (–)-11d (IC50 = 0.19 µM), possesses 
greater anti-HIV-RT activity than all of the NRTIs (IC50 = 0.316-10 μM) tested in their study, with the 
exception of AZT (IC50 = 0.1 μM) that showed comparable activity. Our data obtained for AZT-TP, 
ddCTP and ddATP are in agreement with these findings (Table 1). These data illustrate the remarkable 
potency of the novel phosphononucleoside derivatives 11a-d. The most interesting property of the α-
carboxy nucleoside phosphonate derivatives is the fact that they are directly inhibitory against HIV-1 
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RT without the need for prior metabolic conversion to a higher (mono- or di-) phosphate derivative. 
Indeed, whereas AZT and tenofovir need to be activated (phosphorylated) by cellular nucleoside- and 
nucleotide kinases to their respective 5′-tri- and diphosphate derivatives in the virus-infected cells, the 
α-CNPs do not require such metabolic activation steps. In fact, the thymine α-CNP (–)-11a was found 
to lack substrate activity for thymidine kinase and NDP kinase and (–)-11b and (–)-11c lacked 
substrate activity for UMP/CMP kinase and NDP kinase (data not shown). Thus, in this respect, the 
novel agents represent a conceptually and structurally different class of compounds compared with the 
metabolism-dependent AZT and tenofovir derivatives. The data obtained with the different 
homopolymeric template/primers and corresponding natural dNTP substrates also revealed that the 
compounds are base-specific competitive inhibitors of HIV-1 RT, like AZT-TP and tenofovir 
diphosphate. Also, like AZT-TP and tenofovir diphosphate the α-CNPs inhibit the closely related 
HIV-2 RT within the same order of magnitude as HIV-1 RT in a biochemical assay. 
 
3. Conclusion 
In conclusion, we designed and developed synthetic methodology for the first examples of a series of 
conceptually entirely novel phosphonate derivatives of carbocyclic nucleosides, through the 
incorporation of a carboxylic acid moiety adjacent to the phosphonic acid. We prepared saturated, 
unsaturated and oxygenated cyclopentane derivatives featuring this stuctural motif. A number of these 
new compounds have displayed pronounced inhibitory activity against HIV-1-RT, providing new lead 
compounds in the nucleoside phosphonate field. Both the phosphonate and carboxyl moieties are 
required for activity, and the activity resides in the L-enantiomer of the compounds. The new principle 
of the reported triphosphate mimics may open entirely novel avenues of biological applications given 
the role of nucleotide triphosphates as important and ubiquitous molecules in living systems. Further 
studies are underway to prepare additional α-CNP derivatives and to reveal the molecular mechanism 
of anti-HIV-1 RT activity. Also, lipophilic prodrug derivatives for testing in cellular assays will be 
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synthesized with initial preference for bis(POM), bis(POC) and phosphoramidate derivatives since 
such nucleoside phosphonate prodrug entities have proven clinical efficacy. 
 
4. Experimental 
Solvents were distilled prior to use as follows: dichloromethane was distilled from phosphorus 
pentoxide; ethyl acetate was distilled from potassium carbonate; tetrahydrofuran was distilled from 
sodium-benzophenone; ethanol and methanol were distilled from the corresponding magnesium 
alkoxide. Benzene was dried before use with activated 4Å molecular sieve. Organic phases were dried 
using anhydrous magnesium sulfate. All commercial reagents were used without further purification. 
Microwave reactions were carried out using a CEM Discover in conjunction with Synergy software, 
reaction temperatures were measured by IR sensor. 1H, 13C, 31P and 19F NMR spectra were recorded at 
20 °C on 300, 400 or 600 MHz spectrometers. Chemical shifts are given in ppm relative to 
tetramethylsilane (TMS) as an internal standard. 31P chemical shifts are referenced to H3PO4 (external 
standard) and 19F chemical shifts are referenced to C6F6. Coupling constants (J) are given in hertz 
(Hz). Infrared spectra were recorded as potassium bromide (KBr) discs for solids or thin films on 
sodium chloride plates for oils. Melting points were measured using a capillary melting point 
apparatus and are not corrected. Optical rotations were measured at 20 °C at 589 nm in a 10 cm cell; 
concentrations (c) are expressed in g/100 ml, [α] is expressed in units of 10−1 deg cm2 g−1. Low 
resolution mass spectra were recorded in electrospray ionisation (ESI) mode, high resolution mass 
spectra (HRMS) were recorded on a Time of Flight spectrometer in electrospray ionisation (ESI) 
mode. Column chromatography was performed using silica gel 60. Thin layer chromatography (TLC) 
was carried out on precoated silica gel plates (60 PF254). Visualization was achieved by UV (254 nm) 
detection and/or staining with vanillin, phosphomolybdic acid or permanganate. The acetoxy alcohol 
14, 56  and trimethyl- 57  and triethyl phosphonodiazoacetate 58  were prepared as described in the 




O-H insertion reactions 
cis-1-[(Methoxycarbonyl)dimethylphosphonomethoxy]-4-acetoxycyclopent-2-ene 15 
Rhodium(II) acetate (8 mg, 0.018 mmol, 0.1 mol%) was added to a degassed solution of acetoxy 
alcohol 14 (2.309g, 16.24 mmol) and trimethyl diazophosphonoacetate (3.712 g, 17.85 mmol) in 
benzene (35 mL). The reaction mixture was stirred while heating under reflux for 5 h under a nitrogen 
atmosphere. The mixture was concentrated and the residue purified by flash chromatography (5% 
MeOH/CH2Cl2) to give 15 as a pale yellow oil (3.873 g, 78% yield, dr 1:1); νmax/cm−1 (film) 2960 
(CH), 1733 (C=O), 1438, 1373, 1244 (P=O), 1111, 1031 (C-O); 1H NMR (300 MHz, CDCl3) δ: 1.75 
(dt, J = 14.7, 3.9, 0.5H), 1.86 (dt, J = 15.0, 3.9, 0.5H), 2.05 (s, 0.5H), 2.06 (s, 0.5H), 2.71–2.84 (m, 
1H), 3.81–3.89 (m, 6H), 3.87–3.91 (m, 3H), 4.49 (d, JPH = 20.4, 0.5H), 4.52 (d, JPH = 19.8, 0.5H), 
4.60–4.67 (m, 0.5H), 4.69–4.76 (m, 0.5H), 5.45-5.52 (m, 1H), 6.04–6.16 (m, 2H); 13C NMR (75.5 
MHz, CDCl3) δ: 21.05, 21.07, 36.7, 36.8, 52.9, 54.2-54.4 (m), 73.3 (d, JPC = 159.5), 73.9 (d, JPC = 
159.8), 76.2, 76.3, 84.00 (br d, JPC ≈ 11.3), 84.04 (br d, JPC ≈ 12.0), 134.37, 134.42, 135.18, 135.23, 
168.1 (d, JPC = 2.6), 168.2 (d, JPC = 2.8), 170.6 170.7; 31P NMR (121.5 MHz, CDCl3) δ: 16.5, 16.8; 





This was synthesized using the procedure described above for 15 using acetoxy alcohol (+)-(1R,4S)-14 
(1.491 g, 10.49 mmol) and trimethyl diazophosphonoacetate (2.209 g, 10.62 mmol) in benzene (35 
mL) and a spatula tip of rhodium(II) acetate. The reaction was stirred while heating under reflux for 17 
h. Purification by flash chromatography (5% MeOH/CH2Cl2) afforded (−)-(1S,4R)-15 as a pale yellow 
oil (2.82 g, 88% yield, 98% ee, dr 1:1); [α]20D  – 10.58 (c 0.95, CH2Cl2). The enantiopurity of (−)-(1S, 
4R)-15 was assigned on the basis of the enantiopurities of the acetoxy alcohol (+)-(1R, 4S)-14 and of 






This was synthesized using the procedure described above for 15 from the acetoxy alcohol (−)-(1S, 
4R)-14 (262 mg, 1.84 mmol, 30% ee) and trimethyl diazophosphonoacetate (415 mg, 2.00 mmol) and  
a spatula tip of rhodium(II) acetate in benzene (20 mL). The reaction mixture was stirred while heating 
under reflux for 6 h. Following purification by flash chromatography (5% MeOH/CH2Cl2) the product 
(+)-(1R, 4S)-15 was isolated as a clear oil (545 mg, 92% yield, 30% ee, dr 1:1); [α]20D  + 3.50 (c 0.3, 
CH2Cl2). The enantiopurity of (+)-(1R, 4S)-15 was assigned on the basis of the enantiopurity of the 
acetoxy alcohol (−)-(1S, 4R)-14 and of the base insertion product (−)-(1S,4R)-17b. 
 
cis-1-[(Ethoxycarbonyl)diethylphosphonomethoxy]-4-acetoxycyclopent-2-ene 16 
A solution of acetoxy alcohol 14 (259 mg, 1.82 mmol) and triethyl diazophosphonoacetate (500 mg, 
2.0 mmol) in benzene (20 mL) was added to a flame dried 50 mL round bottomed flask containing 
activated 3Å molecular sieve powder (336 mg). The solution was degassed prior to the addition of 
copper(II) trifluoromethanesulfonate (28 mg, 0.08 mmol, 4 mol%), and heated in a pre-equilibrated oil 
bath at 92 °C for 19 h. The mixture cooled, filtered and concentrated in vacuo. Purification by flash 
chromatography (SiO2, neat Et2O) afforded 16 as a colourless oil (459 mg, 69%, dr 1.2:1); υmax/cm−1 
(film) 3459, 2986 (CH), 2939 (CH), 1737 (C=O), 1645 (C=C), 1442, 1371, 1248 (P=O), 1113 (C-N), 
1024 (C-O); 1H NMR (300 MHz, CDCl3) δ: 1.10–1.42 (m, 9H) 1.71–1.80 (dt, J = 14.4, 4.2, 0.4H) 
1.82–1.91 (dt, J = 15.0, 3.6, 0.6 H), 2.04 (s, 1.2H), 2.05 (s, 1.8H), 2.77 (dt, J = 15.0, 7.2, 1H), 4.16–
4.35 (m, 6H), 4.42 (d, JPH = 19.2, 0.4H), 4.45 (d, JPH = 18.0, 0.6 H), 4.60–4.65 (m, 0.4H), 4.69–4.74 
(m, 0.6H), 5.45–5.50 (m, 1H), 6.03–6.08 (m, 1H), 6.10–6.15 (m, 1H); 13C NMR (150.9 MHz, CDCl3) 
δ: 14.1, 16.39, 16.43, 21.06, 21.09, 36.8, 36.9, 61.88, 61.93, 63.7, 63.8, 73.9 (d, JPC = 158.6), 74.4 (d, 
JPC = 158.9), 76.3, 76.4, 83.90 (d, JPC = 11.6), 83.91 (d, JPC = 12.4), 134.1, 134.7, 134.9, 135.5, 167.8 
(br d, JPC ≈ 2.0), 167.9 (br d, JPC ≈ 2.3), 170.68, 170.70; 31P NMR (121.5 MHz, CDCl3) δ: 14.2, 16.5; 
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HRMS (ES+): calcd for C15H26O8P (M + H)+ 365.1365, found: 365.1372; MS (ES+) m/z: 387.1 (M + 
Na)+, 365.1 (M + H)+. 
 
Base insertion reactions 
General procedure for base insertion reactions. 
A mixture of 2M Na2CO3 (~ 1.2 eq), nucleobase (~ 1.5 eq) and allylic acetate 15 (1 eq), in MeCN was 
thoroughly degassed prior to the addition of a solution of the palladium catalyst (5–10 mol%). The 
reaction mixture was stirred at the specified temperature for the specified amount of time, allowed to 
cool, diluted with CH2Cl2 and filtered by gravity. The solvents were removed under reduced pressure 
and the residue was purified by flash chromatography (SiO2, 5% MeOH/CH2Cl2). 
 
cis-1-{[4-(Methoxycarbonyl)dimethylphosphonomethoxy]cyclopent-2-en-1-yl}thymine 17a 
This was prepared following the general procedure starting from Na2CO3 (2M, 0.35 mL, ~ 0.7 mmol), 
thymine (112 mg, 0.89 mmol), allylic acetate 15 (186 mg, 0.58 mmol) and Pd(PPh3)4 (54 mg, 0.047 
mmol) in acetonitrile (15 mL). The reaction mixture was stirred at 66 °C for 24 h. Purification by flash 
chromatography gave 17a as a cream solid (115 mg, 51%, dr 1.2:1). mp 134–138 °C; (Found: C, 
46.27; H, 5.45; N, 6.86. C15H21N2O8P requires C, 46.40; H, 5.38; N, 7.21%); νmax/cm−1 (KBr) 3176 
(NH), 3042, 2959 (CH), 1754 (C=O), 1689 (C=O), 1663 (C=O), 1640 (C=C), 1470 (CH), 1264 (P=O), 
1102 (C-N), 1029 (C–O); 1H NMR (300 MHz, CDCl3) δ: 1.73–1.85 (m, 1H), 1.94 (d, J = 1.2, 3H), 
2.73–2.87 (m, 1H), 3.81–3.90 (m, 9H), 4.50 (d, JPH = 19.8, 0.55H), 4.53 (d, JPH = 19.2, 0.45H), 4.58–
4.64 (m, 0.55H), 4.64–4.71 (m, 0.45H), 5.62–5.73 (m, 1H), 5.91–6.00 (m, 1H), 6.25–6.35 (m, 1H), 
7.27 (br q, J ≈ 1.2, 0.45H), 7.32 (br q, J ≈ 1.2, 0.55H), 9.13 (br s, 1H); 13C NMR (75.5 MHz, CDCl3) δ: 
12.3, 36.9, 37.1, 53.0, 53.9-54.3 (m), 57.8, 57.9, 74.86 (d, JPC = 159.6), 74.93 (d, JPC = 159.5), 84.7 (d, 
JPC = 10.0), 84.8 (d, JPC = 11.6), 111.5, 111.6, 134.7, 134.9, 135.4, 135.9, 137.1, 137.2, 151.1, 163.9, 
167.6 (br d, JPC ~ 2.5), 167.9 (br d, JPC ~ 2.3); 31P NMR (121 MHz, CDCl3) δ: 16.3, 16.5; HRMS 






This was prepared following the general procedure starting from Na2CO3 (2M, 2.25 mL, ~ 4.50 
mmol), thymine (714 mg, 5.66 mmol), allylic acetate (−)-(1S,4R)-15 (98% ee) (1.25 g, 3.88 mmol), 
Pd(dba)2 (112 mg, 0.21 mmol, 6 mol%) and dppb (182 mg, 0.427 mmol, 11 mol%) in acetonitrile (50 
mL). The reaction mixture was stirred for 5.5 h at 50 °C. Purification by flash chromatography yielded 
(+)-(1R,4S)-17a as a cream solid (831mg, 55%, 98% ee, dr 1.2:1). mp 134–135 °C; [α]20D   + 43.70 (c 
1.00, CH2Cl2). The enantiopurity of (+)-(1R,4S)-17a was assigned on the basis of the enantiopurities of 




This was prepared following the general procedure starting from Na2CO3 (2M, 0.7 mL, ~ 1.40 mmol), 
thymine (234 mg, 1.85 mmol) allylic acetate (+)-(1R, 4S)-15 (70% ee) (395 mg, 1.23 mmol) Pd(dba)2 
(54mg, 0.10 mmol, 8 mol%) and dppb (60mg, 0.141 mmol, 11 mol%) in acetonitrile (20 mL). The 
reaction mixture was stirred for 5.5 h at 50 °C. Purification by flash chromatography yielded (−)-
(1S,4R)-17a as a cream solid (261mg, 55%, 70% ee, dr 1.2:1). mp 136–137 °C; [α]20D  − 33.22 (c 0.90, 
CH2Cl2). The enantiopurity of (−)-(1S,4R)-17a was assigned on the basis of the enantiopurities of the 
acetoxy alcohol (−)-(1S,4R)-15 and of the saturated product (+)-(1R,4S)-18a. 
 
cis-1-{4-[(Methoxycarbonyl)dimethylphosphonomethoxy]cyclopent-2-en-1-yl}uracil 17b 
This was prepared following the general procedure starting from Na2CO3 (2M, 0.6 mL, ~ 1.2 mmol), 
uracil (171 mg, 1.52 mmol), allylic acetate 15 (324 mg, 1.01 mmol), and Pd(PPh3)4 (58 mg, mmol, 5 
mol%) in acetonitrile (30 mL). The reaction mixture was stirred at 66 °C for 24 h. Purification via 
flash chromatography afforded the pure product 17b as a cream gum (148 mg, 38%, dr 1.2:1); 
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νmax/cm−1 (film) 3480, 3177 (NH), 3057 (CH), 2961 (CH), 1750 (C=O), 1689, 1625, 1462, 1380, 1260 
(P=O), 1105 (C-N), 1032 (C-O); 1H NMR (300 MHz, CDCl3) δ: 1.74-1.86 (2 × overlapping apparent 
dt, J = 10.8, 2.7, 8.1, 3.0, 1H), 2.74–2.87 (apparent dt, J = 15.3, 7.5, 1H), 3.80–3.90 (m, 9H), 4.50 (d, 
JPH = 19.8, 0.5H), 4.53 (d, JPH = 19.2, 0.5H), 4.59–4.65 (m, 0.5H), 4.66–4.72 (m, 0.5H), 5.64–5.72 (m, 
1H), 5.74 (br d, J ~ 8.1, 1H), 5.93–6.01 (m, 1H), 6.28–6.37 (m, 1H), 7.49 (d, J = 8.1, 0.5H), 7.51 (d, J 
= 8.1, 0.5H), 9.46 (br s, 1H); 13C NMR (75.5 MHz, CDCl3) δ: 36.9, 37.3, 53.0, 54.1 (2 × overlapping 
d, JPC ≈ 6.6, 6.6), 54.2 (d, JPC = 6.3), 54.3 (d, JPC = 6.2), 58.08, 58.11, 74.78 (d, JPC = 159.8), 74.81 (d, 
JPC = 160.1), 84.5 (d, JPC = 9.6), 84.6 (d, JPC = 11.7), 102.9, 134.2, 134.6, 135.8, 136.4, 141.6, 151.1, 
163.4, 167.5 (br d, JPC ≈ 2.5), 167.8 (br d, JPC ≈ 2.5); 31P NMR (121.5 MHz, CDCl3) δ: 16.3, 16.5; 





This was prepared following the general procedure starting from Na2CO3 (2M, 0.7 mL, ~ 1.40 mmol), 
uracil (208 mg, 1.86 mmol), allylic acetate (−)-(1S,4R)-15 (98% ee) (395 mg, 1.23 mmol), Pd(dba)2 
(38 mg, 0.07 mmol, 6 mol%) and dppb (52 mg, 0.12 mmol, 10 mol%) in acetonitrile. The reaction 
mixture was stirred for 5.5 h at 50 °C Purification by flash chromatography afforded (+)-(1R,4S)-17b 
as a cream hygroscopic gum (294 mg, 64%, 98% ee, dr 1.2:1). [α]20D  + 19.56 (c 2.30, CH2Cl2); HPLC 
conditions: CHIRALCEL® OJ-H column, 30:70 isopropanol:hexane, 0.7 mL/min. 49.2 min, 59.3 min, 




This was prepared following the general procedure starting from Na2CO3 (2M, 1.4 mL, ~2.80 mmol), 
uracil (422 mg, 3.77 mmol), allylic acetate (+)-(1R, 4S)-15 (30% ee) (801 mg, 2.5 mmol), Pd(dba)2 (94 
26 
 
mg, 0.18 mmol, 7 mol%) and dppb (107 mg, 0.25 mmol, 10 mol%) in acetonitrile (30 mL). The 
reaction mixture was stirred for 2.5 h at 55 °C. Purification by flash chromatography afforded the 
product (−)-(1S,4R)-17b as a cream hygroscopic gum (511 mg, 55%, 30% ee dr 1:1). [α]20D  − 5.87 (c 
2.23, CH2Cl2); HPLC conditions: CHIRALCEL® OJ-H column, 30:70 isopropanol:hexane, 0.7 
mL/min. 49.2 min, 59.3 min, 83.6 min, 115.0 min.  
 
cis-1-{4-[(Methoxycarbonyl)dimethylphosphonomethoxy]cyclopent-2-en-1-yl}cytosine 17c 
This was prepared following the general procedure starting from Na2CO3 (2M, 0.45 mL, ~0.90 mmol), 
cytosine (128 mg, 1.17 mmol), allylic acetate 15 (255 mg, 0.79 mmol), Pd(dba)2 (25 mg, 0.05 mmol, 6 
mol%) and dppb (36 mg, 0.08 mmol, 10 mol%) in acetonitrile (10 mL). The reaction mixture was 
irradiated (50 W, 55 °C) for 1 h. Purification by flash chromatography afforded 17c as a cream 
hygroscopic gum (105 mg, 36%, dr 1:1). νmax/cm−1 (film) 3423 (NH), 3194 (CH), 2957 (CH), 2853 
(CH), 1736 (C=O), 1723 (C=O), 1649, 1233 (P=O), 1101 (C-N), 1051 (C-O); 1H NMR (300 MHz, 
CDCl3) δ: 1.67–1.80 (2 overlapping dt, J = 10.2, 2.7, 10.2, 3.0, 1H), 2.76–2.90 (m, 1H), 3.79–3.99 (m, 
9H), 4.47 (d, JPH = 19.8, 0.5H), 4.50 (d, JPH = 19.5 0.5H), 4.56–4.62 (m, 0.5H), 4.65–4.71 (m, 0.5H), 
5.10–7.00 (br s, 2H), 5.76–5.88 (m & d at 5.83, J ≈ 7.2, 2H), 5.94-6.02 (m, 1H), 6.23–6.30 (m, 1H), 
7.52 (d, J = 7.2, 0.5H), 7.54 (d, J = 7.2, 0.5H); 13C NMR (75.5 MHz, CDCl3) δ: 37.5, 37.8, 53.0, 54.1–
54.4, 58.77, 58.83, 74.65 (d, JPC = 160.0), 74.72 (d, JPC = 159.8, PCH), 85.0 CH, d, J ≈ 9.7), 86.0 (br d, 
J ≈ 12.5), 95.2, 134.8, 135.2, 135.5, 135.8, 142.7, 156.3, 165.2, 167.7 (br d, JPC ≈ 2.7), 167.9 (br d, JPC 
≈ 2.3); 31P NMR (121.5 MHz, CDCl3) δ: 16.4, 16.8; HRMS (ES+): calcd for C14H21N3O7P (M + H)+ 




This was prepared following the general procedure starting from Na2CO3 (2M, 0.66 mL, ~ 1.32 
mmol), cytosine (202 mg, 1.82 mmol) allylic acetate (−)-(1S,4R)-15 (98% ee) (390 mg, 1.21 mmol), 
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and Pd(dba)2 (35 mg, 0.07 mmol, 5 mol%) and dppb (52 mg, 0.12 mmol, 10 mol%), in acetonitrile (25 
ml). The mixture was stirred for 3 h at 55 °C. Purification by flash chromatography afforded (+)-
(1R,4S)-17c as a light brown gum (178 mg, 39% yield, 98% ee, dr 1.1:1). [α]20D  + 24.50 (c 0.1, 
CH2Cl2). The enantiopurity of (+)-(1R,4S)-17c was assigned on the basis of the enantiopurity of the 




This was prepared following the general procedure starting from Na2CO3 (2M, 1.5 mL ~ 3.0 mmol), 
cytosine (441 mg, 3.97 mmol) allylic acetate (+)-(1R,4S)-15 (70% ee) (848 mg, 2.63 mmol), Pd(dba)2 
(104 mg, 0.2 mmol, 7.5 mol%) and dppb (114 mg, 0.27 mmol, 10 mol%) in acetonitrile (45 mL). The 
reaction mixture was stirred for 6.5 h at 55 °C. Purification by flash chromatography afforded (−)-
(1S,4R)-17c as a pale brown gum (356 mg, 36%, 70% ee, dr 1.2:1). [α]20D  − 18.25 (c 0.2, CH2Cl2). The 




This was prepared following the general procedure starting from Cs2CO3 (2 M, 0.7 mL, ~ 1.43 mmol), 
adenine (316 mg, 2.34 mmol), the allylic acetate 15 (458 mg, 1.42 mmol), Pd2(dba3).CHCl3 (80 mg, 
0.09 mmol, 6 mol%) and dppb (67mg, 0.16 mmol, 11 mol%) in acetonitrile (25 mL). The reaction 
mixture was stirred for 5.5 h at 50 °C. Purification by flash chromatography yielded 17d as a cream 
hygroscopic gum (153 mg, 27% dr 1:1). νmax/cm−1 (film) 3392 (NH), 3185, 2958 (CH), 1749 (C=O), 
1655, 1599 (C=C), 1235 (P=O), 1104 (C-N), 1035 (C-O); 1H NMR (300 MHz, CDCl3) δ: 2.01–2.17 (2 
dt, J = 9.6, 3.0, 9.3, 3.0, 1H), 2.84–3.00 (m, 1H), 3.78–3.92 (m, 9H), 4.55 (d, JPH = 20.1, 0.5H), 4.65 
(d, JPH = 19.5, 0.5H), 4.70–4.77 (m, 0.5H), 4.79–4.86 (m, 0.5H), 5.61–5.70 (m, 1H), 6.10–6.31 (m, 
3H), 6.34–6.41 (m, 1H), 8.10 (s, 0.5H), 8.11 (s, 0.5H), 8.35 (s, 1H); 13C NMR (75.5 MHz, CDCl3) δ: 
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38.2, 38.6, 53.06, 53.08, 54.0-54.5 (4 overlapping d, J ≈ 6.7, 6.8, 6.7, 6.6), 56.5, 56.6, 74.5 (d, JPC = 
159.6), 74.6 (d, JPC = 159.8), 84.5 (d, JPC = 10.5), 84.8 (d, JPC = 11.8), 119.46, 119.48, 134.5, 134.8, 
135.2, 135.6, 139.59, 139.64, 149.52, 149.54, 152.9, 155.59, 155.61, 167.7 (d, JPC = 2.2), 167.9 [d, JPC 
= 2.5); 31P NMR (121 MHz, CDCl3) δ: 16.3, 16.6; HRMS (ES+): calcd for C15H21N5O6P (M+H)+ 




This was prepared following the general procedure starting from Cs2CO3 (2M, 1.35 mL, ~ 2.7 mmol), 
adenine (521 mg, 3.86 mmol) allylic acetate (−)-(1S,4R)-15 (98% ee) (701 mg, 2.18 mmol), Pd(dba)2 
(75 mg, 0.14 mmol, 7 mol%) and dppb (123 mg, 0.29 mmol, 13 mol%) in acetonitrile (70 mL). The 
reaction mixture was then stirred for 5 h at 50 °C. Purification by flash chromatography afforded (+)-
(1R,4S)-17d as a cream hygroscopic gum (279 mg, 32%, 98% ee, dr 1.1:1). The enantiopurity of (+)-





This was prepared following the general procedure starting from Cs2CO3 (2M, 1.0 mL, ~2.0 mmol), 
adenine (352 mg, 2.56 mmol) allylic acetate (+)-(1R,4S)-15 (70% ee) (551 mg, 1.70 mmol), Pd(dba)2 
(62mg, 0.12 mmol, 6 mol%) and dppb (80 mg, 0.19 mmol, 11 mol%) in acetonitrile (25 mL). The 
reaction mixture was stirred for 2.5 h at 55 °C. Purification by flash chromatography afforded (−)-
(1S,4R)-17d as a cream hygroscopic gum (268 mg, 40%, 70% ee, dr 1.1:1). The enantiopurity of (−)-






chloropurine N-9-17e and  
cis-2-Amino-7-[{4-(methoxycarbonyl)dimethylphosphonomethoxy}cyclopent-2-en-1-yl]-6-
chloropurine N-7-17e  
This was prepared following the general procedure starting from Cs2CO3 (2M, 0.95 mL, ~ 1.89 mmol), 
2-amino-6-chloropurine (432 mg, 2.55 mmol) allylic acetate 15 (550 mg, 1.70 mmol), Pd(dba)3 (50 
mg, 0.15 mmol, 5 mol%) and dppb (73 mg, 0.17 mmol, 10 mol%) in acetonitrile (25 mL). The reaction 
mixture stirred for 6.5 h at 45 °C. Purification by flash chromatography afforded N-9-17e (101 mg, 
14% dr 1.2:1) as a pale yellow oil, and N-7-17e (253 mg, 35% dr 1.2:1) as a yellow oil. 
N-9-17e: 1H NMR (300 MHz, CDCl3) δ: 2.09 (dt, J = 15.0, 3.3, 0.45H), 2.32 (dt, J = 15.0, 4.5, 0.55H), 
2.83–3.02 (m, 1H), 3.79–3.89 (m, 9H), 4.78 (d, JPC = 20.4, 0.45H), 4.79–4.86 (m, 0.45H), 4.99–5.06 
(m, 0.55H), 5.25–5.39 (m, 2.1H), 5.41–5.48 (m, 1H,), 5.54 [br s, 1H), 6.04–6.12 (m, 1H), 6.22–6.28 
(m, 0.55H), 6.34–6.39 (m, 0.45H), 7.88 (br s, 0.55H), 7.97 (br s, 0.45H). 
N-7-17e: νmax/cm–1 (KBr) 3440, 3401, 3327 (NH), 3209 (CH), 2958 (CH), 1749 (C=O), 1626, 1544, 
1496 (CH), 1378, 1257, 1226 (P=O), 1107 (C-N), 1028 (C-O); 1H NMR (300 MHz, CDCl3) δ: 1.98–
2.14 (2 dt, J = 14.7, 2.7, 15.0, 3.0, 1H), 2.87–3.03 (m, 1H), 3.72–3.90 (m, 9H), 4.48 (d, JPC = 19.8, 
0.55H), 4.52 (d, JPC = 19.2, 0.45H), 4.69–4.75 (m, 0.55H), 4.77–4.83 (m, 0.45H), 5.33 (br s, 2H), 
5.76–5.86 (m, 1H), 6.21–6.29 (m, 1H,), 6.43–6.51 (m, 1H,), 8.19 (br s,0.45H), 8.20 (br s, 0.55H); 13C 
NMR (75.5 MHz, CDCl3) δ: 39.4, 39.8, 53.08, 53.10, 54.1-54.5 (m), 59.7, 59.8, 74.89 (d, JPC = 159.6), 
74.94 (d, JPC = 159.8), 84.5 (d, JPC = 10.7), 84.7 (d, JPC = 12.3), 132.7, 133.3, 134.0, 136.4, 137.1, 
143.1, 146.9, 159.3, 164.4, 167.6 (d, J = 2.2), 167.8 (d, J = 2.5); 31P NMR (121.5 MHz, CDCl3) δ: 
16.0, 16.2. Peaks due to unknown impurity (~ 10%) visible in 13C NMR spectrum at 141.8, 159.1 ppm 






This was prepared following the general procedure starting from Na2CO3 (2M, 0.35 mL, 0.7 mmol) 5-
fluorouracil (113 mg, 0.87 mmol), allylic acetate 15 (186 mg, 0.58 mmol) Pd(PPh3)4 (54 mg, 0,046 
mmol) and in acetonitrile (15 mL). The reaction mixture was stirred at 60 °C for 2.5 h. Purification via 
flash chromatography (3% MeOH/CH2Cl2) afforded 17f as a beige solid (94 mg, 41%, dr 1:1). mp 141 
°C; νmax/cm–1 (film): 3486, 3171 (NH), 3066 (CH), 2961 (CH), 1750, 1713 (C=O), 1665, 1467, 1438, 
1389, 1260 (P=O), 1104 (C-N), 1033 (C-O); 1H NMR (300 MHz, CDCl3) δ: 1.80–1.87 (m, 1H), 2.67–
2.80 (m, 1H), 3.81–3.87 (m, 9H), 4.51 (d, J = 20.0, 0.5H), 4.53 (d, J = 19.3, 0.5H), 4.58–4.60 (m, 
0.5H), 4.66–4.67 (m, 0.5H), 5.65–5.71 (m, 1H), 5.94–6.00 (m, 1H), 6.30–6.37 (m, 1H), 7.64 (d, J = 
6.8z, 0.5H), 7.66 (d, J = 6.6Hz, 0.5H), 9.93 (br s, 1H); 13C NMR (75.5 MHz, CDCl3) δ: 36.6, 36.9, 
53.2, 54.18, 54.26, 54.31, 54.35, 58.69, 58.74, 74.8 (d, J = 159.7), 84.3 (d, J = 9.6), 84.6 (d, J = 11.5), 
125.9 (d, J = 33.5), 126.0 (d, J = 33.4), 134.4, 134.7, 136.2, 136.7, 140.9 (d, J = 237.7), 149.8, 157.1 
(d, J = 26.5), 167.6 (d, J = 2.5), 167.8 (d, J = 2.4Hz); 13P NMR (121.5 MHz, CDCl3) δ: 16.26, 16.45; 
19F NMR (282.4 MHz, CDCl3) δ: − 164.23, − 164.16; HRMS (ES+) calcd for C14H19FN2O8P (M + H)+ 




A mixture of alkene 17a (108 mg, 0.28 mmol) and 10% palladium on carbon (54 mg) in methanol (10 
mL) was pressurized with hydrogen to 30 psi and shaken for 2.5 h. The mixture was filtered on Celite 
and the cake was rinsed with methanol. The filtrate was concentrated and the residue was purified by 
flash chromatography (5% MeOH in CH2Cl2) to give 18a as a cream solid (100 mg, 92%, dr 1.1:1). 
mp 130–133 °C; (Found: C, 45.91; H, 5.84; N, 6.90. C15H23N2O8P requires C, 46.16; H, 5.94; N, 
7.18%); νmax/cm−1(KBr) 3183 (NH), 3053, 2960 (CH), 1748 (C=O), 1689 (C=O), 1662 (C=O), 1644 
(C=C), 1469 (CH), 1261 (P=O), 1113 (C-N), 1023 (C-O); 1H NMR (600 MHz, CDCl3) δ: 1.55–1.66 
(m, 1H), 1.76–1.90 (m, 2H), 1.98 (s, 1.5H), 2.00 (s, 1.5H), 2.02–2.07 (br dd, J ≈ 6.6, 7.2, 0.5H), 2.08–
2.14 (br, dd, J ≈ 6.6, 7.2, 0.5H), 2.16–2.25 (m, 1H), 2.35–2.43 (m, 1H), 3.83–3.90 (m 9H), 4.15–4.19 
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(m, 0.5H), 4.20–4.24 (m, 0.5H), 4.40 (d, JPH = 18.6, 0.5H), 4.46 (d, JPH = 19.8, 0.5H), 5.22–5.31 (m, 
1H), 7.66 (s, 0.5H), 7.80 (s, 0.5H), 8.75 (br s, 1H); 13C NMR (75.5 MHz, CDCl3) δ: 12.25, 12.27, 30.0, 
30.1, 30.6, 31.4, 38.4, 38.7, 52.97, 53.00, 53.02, 53.2, 53.8-54.4 (m), 73.3 (d, JPC = 160.8), 74.1 (d, JPC 
= 160.1), 82.0 (d, JPC = 11.3), 82.8 (d, JPC = 9.1), 111.67, 111.8, 138.0, 138.1, 151.45, 151.48, 163.9, 
167.7 (d, J = 2.3), 167.9 (d, J = 2.3); 31P NMR (121.5 MHz, CDCl3) δ: 16.8, 17.0; HRMS (ES+): calcd 




Following the procedure described for 18a starting from (+)-(1R,4S)-17a (98% ee) (636 mg, 1.64 
mmol) and 5% Pd/C (217 mg) in methanol (25 mL) afforded (−)-(1S,4R)-18a as a white solid (584 
mg, 91%, 98% ee, dr 1.1:1); mp 133–135 °C; [α]20D  − 8.48 (c 0.67, CH2Cl2); HPLC conditions: 
CHIRALPAK® AS-H column 25:75 IPA:hexane, flow 0.8 mL/min. Retention times: 48.5 min (not 




Following the procedure described for 18a starting from the alkene (−)-(1S,4R)-17a (50% ee) (167 mg, 
0.43 mmol) and 5% Pd/C (76 mg) in methanol (15 mL) afforded (+)-(1R,4S)-18a as a cream solid 
(143mg, 85%, 50% ee, dr 1:1); mp 129–130 °C; [α]20D  + 6.11 (c 1.24, CH2Cl2); HPLC conditions: 
CHIRALPAK® AS-H column 25:75 IPA:hexane, flow 0.8 mL/min. Retention times: 48.5 min (not 
resolved), 84.1 min, 102.7 min. 
 
cis-1-{4-[(Methoxycarbonyl)dimethylphosphonomethoxy]cyclopentan-1-yl}uracil 18b 
Following the procedure described for 18a starting from 17b (75 mg, 0.19 mmol) and 5% Pd/C (50 
mg) in methanol (10 mL) and shaking for 1.5 h afforded the saturated product 18b as a white 
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hygroscopic gum (69 mg, 86%, dr 1.1:1); νmax/cm−1 (film) 3425 (NH), 3198, 2959, 2921 (CH), 1744 
(C=O), 1688, 1255 (P=O), 1111 (C-N), 1034 (C-O); 1H NMR (600 MHz, CDCl3) δ: 1.57–1.67 (m, 
1H), 1.78–1.90 (m, 2H), 2.04–2.14 [2 dd , J ≈ 6.6, 6.6, 6.6, 6.6, 1H), 2.19–2.29 (m, 1H), 2.34–2.43 (m, 
1H), 3.83–3.89 (m, 9H), 4.17–4.22 (m, 1H), 4.39 (d, JPH = 19.2, 0.55H), 4.44 (d, JPH = 19.8, 0.45H), 
5.21–5.30 (m, 1H), 5.75 (br d, J ≈ 7.8, 0.45H), 5.80 (br d, J ≈ 7.8, 0.55H), 7.89 (br d, J ≈ 8.4, 0.45H), 
7.98 (br d, J ≈ 7.8, 0.55H), 8.87 (br s, 1H,); 13C NMR (75.5 MHz, CDCl3) δ: 30.2, 30.6, 31.6, 38.3, 
38.9, 53.01, 53.02, 53.4, 53.5, 53.9 (d, JPC = 6.6), 54.0 (d, JPC = 6.8), 54.1 (d, JPC = 6.6), 54.4 (d, JPC = 
6.6), 73.4 (JPC = 160.8), 74.1 (d, JPC = 160.0), 82.0 (d, JPC = 11.2, 82.7 (d, JPC = 9.3), 102.9, 103.1, 
142.4, 142.5, 151.38, 151.41, 163.3, 167.6 (br d, JPC ≈ 2.0), 167.9 (br d, JPC ≈ 2.6); 31P NMR (121.5 
MHz, CDCl3) δ: 16.8, 17.0; HRMS (ES+): calcd for C14H22N2O8P (M + H)+ 377.1114, found 




Following the procedure described for 18a starting from (+)-(1R,4S)-17b (98% ee) (231 mg, 0.62 
mmol) and 5% Pd/C (181 mg) in methanol (35 mL) and shaking for 1.5 h afforded (−)-(1S,4R)-18b as 
a cream gum (209 mg, 90%, 98% ee, dr 1.1:1). [α]20D  − 4.55 (c 0.62, CH2Cl2); HPLC Conditions: 
CHIRALCEL® OJ-H column 30:70 IPA:hexane, flow 0.7 mL/min. Retention times: 42.2 min, 47.5 




Following the procedure described for 18a, starting from (−)-(1S,4R)-17b (30% ee) (351 mg, 0.94 
mmol) and 5% Pd/C (120 mg) in methanol (30 mL) and shaking for 1.5 h afforded the (+)-(1R,4S)-18b 
as a white hygroscopic gum (331 mg, 94%, 30% ee, dr 1.1:1). [α]20D  + 1.46 (c 1.13, CH2Cl2); HPLC 
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conditions: CHIRALCEL® OJ-H column 30:70 IPA:hexane, flow 0.7 mL/min. Retention times: 42.2 
min, 47.5 min, 60.6 min, 68.5 min. 
 
cis-1-{4-[(Methoxycarbonyl)dimethylphosphonomethoxy]cyclopentan-1-yl}cytosine 18c 
Following the procedure described for 18a, starting from 17c (97 mg, 0.26 mmol) and 5% Pd/C (60 
mg) in methanol (10 mL) and shaking for 15 h at 25 psi afforded 18c as a white hygroscopic gum (78 
mg, 80%, dr 1.1:1). νmax/cm−1 (film) 3421 (NH), 3198 (CH), 2958 (CH), 1744 (C=O), 1718, 1651, 
1531, 1491 (CH), 1260, 1233 (P=O), 1109 (C-N), 1050 (C-O), 1030; 1H NMR (300 MHz, CDCl3) δ: 
1.58–1.90 (m, 3H), 1.97–2.12 (m, 1H), 2.15–2.30 (m, 1H), 2.34–2.48 (m, 1H), 3.81–3.90 (m, 9H), 
4.12–4.20 (m, 1H), 4.40 (d, JPH = 19.2, 0.5H), 4.44 (d, JPH = 19.8, 0.5H), 5.27–5.44 (m, 1H), 5.50–7.31 
(br s, 2H), 5.90 (d, J = 7.5, 0.5H), 5.93 (d, J = 7.5, 0.5H), 7.86 (d, J = 7.5, 0.5H), 7.94 (d, J = 7.5, 
0.5H); 13C NMR (75.5 MHz, CDCl3) δ: 30.6, 30.7, 31.7, 38.5, 39.0, 53.01, 53.04, 53.9–54.3 (m), 73.5 
(d, JPC = 160.7), 74.1 (d, JPC = 160.0), 82.3 (d, JPC = 11.2, 82.9 (d, JPC = 9.5), 95.2, 95.4, 143.4, 143.6, 
156.9, 164.9, 167.8 (d, JPC = 2.3), 168.0 (d, JPC = 2.7); 31P NMR (121.5 MHz, CDCl3) δ: 16.9, 17.0, 
HRMS (ES+): calcd for C14H23N3O7P (M + H)+ 376.1274, found 376.1263; MS (ES–) m/z: (M – H)–. 




Following the procedure described for 18a, starting from (+)-(1R,4S)-17c (98% ee) (167 mg, 0.447 
mmol) and 10% Pd/C (83 mg) in methanol (25 mL) and shaking for 15h at 25 psi afforded (−)-
(1S,4R)-19c as a colorless hygroscopic gum (98 mg, 58%, 98% ee, dr 1.2:1). Optical rotation could not 
be measured due to instability. The enantiopurity of (−)-(1S,4R)-18c was assigned on the basis of the 






Following the procedure described for 18a, starting from (−)-(1R,4S)-17c (70% ee, 171 mg, 0.46 
mmol) and 10% Pd/C (86 mg) in methanol (35 mL) and shaking for 15 h at 25 psi afforded the (+)-
(1R,4S)-18c as a colorless gum (106 mg, 62%, 70% ee, dr 1.2:1). Optical rotation could not be 
measured due to instability. The enantiopurity of (+)-(1R,4S)-18c was assigned on the basis of the 
enantiopurity of the acetoxy alcohol (−)-(1S,4R)-15. 
 
cis-9-{4-[(Methoxycarbonyl)dimethylphosphonomethoxy]cyclopentan-1-yl}adenine 18d 
Following the procedure described for 18a, starting from N-9-17d (210 mg, 0.53 mmol) and 5% Pd/C 
(75 mg) in methanol (15 mL) and shaking for 19 h afforded 18d as a white hygroscopic gum (169 mg, 
80%, dr 1:1). νmax/cm−1 (film) 3362, 3280 (NH), 3108, 2953, 2922 (CH), 1738 (C=O), 1672, 1601 
(C=C), 1230 (P=O), 1108 (C-N), 1073, 1048 (C-O); 1H NMR (300 MHz, CDCl3) δ: 1.78–1.94 (m, 
1H), 2.06–2.27 (m, 3H), 2.33–2.48 (m, 1H), 2.49–2.64 (m, 1H), 3.82–3.92 (m, 9H), 4.26–4.35 (m, 
1H,), 4.40 (d, JPH = 19.2, 0.5H), 4.49 (d, JPH = 19.8, 0.5H), 5.11–5.24 (m, 1H), 6.02 (br s, 1H), 6.05 (br 
s, 1H), 8.35 (s, 1.5 H), 8.46 (s, 0.5H); 13C NMR (75.5 MHz, CDCl3) δ: 30.7, 31.8, 32.0, 32.1, 39.7, 
40.3, 52.4, 52.5, 53.0, 54.1 (d, JPC = 6.6), 54.3 (d, JPC = 6.6), 54.5 (d, JPC = 6.6), 73.8 (d, JPC = 160.4), 
74.5 (d, JPC = 159.7), 82.0, 82.8, 119.3, 139.8, 139.9, 149.9, 152.8, 155.76, 155.78, 167.7 (d, JPC = 
2.0), 168.0 (d, JPC = 2.3); 31P NMR (121.5 MHz, CDCl3) δ: 16.6, 16.8; HRMS (ES+): calcd for 




Following the procedure described for 18a, starting from (+)-(1R,4S)-17d (98% ee) (158 mg, 0.40 
mmol) and 5% Pd/C (75 mg) in methanol (25 mL) and shaking for 19 h afforded (−)-(1S,4R)-18d as a 
pale yellow hygroscopic gum (118 mg, 74%, 98% ee, dr 1:1); [α]20D  – 4.33 (c 0.15, CH2Cl2). The 
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Following the procedure described for 18a, starting from (−)-(1S,4R)-17d (70% ee) (253 mg, 0.64 
mmol) and 10% Pd/C (100 mg) in methanol (20 mL) and shaking for 19 h afforded (+)-(1R,4S)-18d as 
a pale yellow hygroscopic gum (189 mg, 74%, 70% ee, dr 1.1:1); [α]20D  + 10.00 (c 0.2, CH2Cl2). The 





Following the procedure described for 18a, starting from N-7-17e (161 mg, 0.28 mmol) and 10% Pd/C 
(54 mg) in methanol (10 mL), and shaking for 26 h at 50 psi afforded the saturated compound N-7-18e 
as a cream solid (21 mg, 17%, dr 1:1). 1H NMR (300 MHz, CDCl3) δ: 1.80–2.61 (m, 6H), 3.81–3.90 
(m, 9H), 4.26–4.38 (m, 1H,), 4.40 (d, JPC = 19.2, 0.5H), 4.45 (d, JPC = 20.1, 0.5H), 5.13 (br s,1H), 5.14 
(br s, 1H), 5.31–5.44 (m, 1H), 8.57 (br s, 0.5H), 8.64 (br s, 0.5H); signals for unreacted N-7-17e were 
seen at 5.78–5.89 (m, 0.1H), 6.20–6.27 (m, 0.1H), 6.44–6.50 (m, 0.1H), 8.19 (s, 0.04H) and 8.20 (s, 




A mixture of 17f (61 mg, 0.155 mmol) and 5% Pd/C (30 mg) in methanol (5 mL) was stirred for 16h 
under a balloon of hydrogen. The mixture was filtrated over Celite and the cake was rinsed with 
MeOH. The filtrate was concentrated and the residue was purified by flash chromatography (3% 
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MeOH/CH2Cl2) to afford 18f as a white gum (59 mg, 97% dr 1:1). νmax/cm−1 (film): 3490, 3174 (NH), 
3067, 2961, 2857, 2825 (CH), 1749, 1700 (C=O), 1469, 1438, 1394, 1359, 1319 (C-H), 1265, 1109, 
1032 (C-O, C-N, P-O); 1H NMR (300 MHz, CDCl3) δ: 1.47–2.42 (m, 6H), 3.82–3.87 (m, 9H), 4.15–
4.17 (m, 0.5H), 4.21–4.23 (m, 0.5H), 4.39 (d, J = 19.0, 0.5H), 4.45 (d, J = 20.3, 0.5H), 5.24-5.33 (m, 
1H), 8.06 (d, J = 6.7, 0.5H), 8.18 (d, J = 6.7, 0.5H), 9.34 (m, 1H); 13C NMR (75.5 MHz, CDCl3) δ: 
30.1, 30.2, 30.5, 31.4, 38.7, 39.0, 53.1, 53.4, 53.9, 54.0, 54.2, 54.3, 73.1 (d, J = 160.5), 74.1 (d, J = 
159.3), 81.9 (d, J = 11.4), 83.0 (d, J = 8.6), 126.8 (d, J = 34.3), 140.9 (d, J = 236.2), 141.0 (d, J = 
236.1), 150.1, 156.9 (d, J = 26.6), 167.5 (d, J = 2.0), 167.9 (d, JPC = 2.9); 31P NMR (121.5 MHz, 
CDCl3) δ: 16.64, 16.92; 19F NMR (282.4 MHz, CDCl3) δ: − 164.08, − 164.06; HRMS (ES+) calcd for 
C14H21FN2O8P (M + H)+ 395.1020, found 395.1013; MS (ES–) m/z: 393.3 (M – H)–. 
 
Deprotection reactions. General procedure for partial deprotection 
A solution of the protected compound 18 (1 eq) in CH2Cl2 or acetonitrile was treated with TMSBr (5 
eq). The mixture was flushed with nitrogen, sealed and stirred at ambient temperature overnight, or 
irradiated (50 °C, 50 W) for 15 min, after which water (1 mL) was added and stirring was continued 
for 30 min. The mixture adjusted to pH 7 with 10% NaOH, the solvents were removed under reduced 
pressure (bath temp < 30 °C) and the residue was purified by charcoal chromatography, eluting with 
10:10:3 EtOH/H2O/conc. NH4OH. 
 
General procedure for full deprotection 
A solution of the protected compound 18 (1 eq) in CH2Cl2 or acetonitrile was treated with TMSBr (5 
eq). The mixture was flushed with nitrogen, stirred at ambient temperature overnight, or sealed and 
irradiated (50 °C, 50 W) for 15 min, after which water (1 mL) was added and stirring was continued 
for 30 min. The volatiles were removed and 1M NaOH (10 eq) was added. The resulting solution was 
stirred overnight at room temperature, then concentrated, and the residue was purified by charcoal 





This was prepared following the general procedure for partial deprotection, starting from 18a (93 mg, 
0.25 mmol) and TMSBr (0.17 mL, 191 mg, 1.25 mmol) CH2Cl2, and the reaction mixture was stirred 
overnight. Purification by a charcoal column afforded 19a as the ammonium salt (77 mg, 82%, dr 1:1); 
1H NMR (300 MHz, D2O) δ: 1.51–2.04 (m, 5H,), 1.785 (s, 1.5H), 1.790 (s, 1.5H), 2.26–2.36 (m, 1H,), 
3.66 (s, 1.5H), 3.67 (s, 1.5H), 3.99–4.10 (m, 1H), 4.24 (d, JPH = 18.6, 0.5H), 4.27 (d, JPH = 18.9, 0.5H), 




This was prepared following the general procedure for full deprotection, starting from 18a (133 mg, 
0.34 mmol) and TMSBr (260 mg, 0.22 mL, 1.7 mmol) in CH2Cl2 (20 mL) at 0 °C, stirred overnight at 
room temperature, followed water (1 mL) and NaOH (1M, 3.5 mL, ~3.5 mmol, 10 eq.). Purification by 
charcoal chromatography gave the fully deprotected phosphonate 11a as the ammonium salt (56 mg, 
45%, dr 1:1). mp 228–230 °C; νmax/cm−1 (KBr) 3152 (NH), 3025 (CH), 1691 (C=O), 1405, 1273 
(P=O), 1058; 1H NMR (600 MHz, D2O) δ: 1.53–1.62 (m, 0.5H), 1.62–1.75 (m, 2.5H), 1.76 (s, 3H), 
1.80–1.98 (m, 2H), 2.24–2.31 (m, 1H), 3.92 (d, PCH, JPC = 18.6, 0.5H), 3.95–4.02 (m, 1.5H), 4.73–
4.84 (m, 1H), 7.70 (s, 0.5H), 7.72 (s, 0.5H); 13C NMR (150.9 MHz, D2O) δ: 11.4, 11.5, 29.1, 29.2, 
29.5, 30.6, 36.6, 37.5, 54.6, 54.8, 77.5 (d, JPC = 143.5), 78.2 (d, JPC = 143.4), 79.9 (d, JPC = 11.2), 80.6 
(d, JPC = 10.9), 111.3, 111.4, 140.3, 140.5, 152.57, 152.59, 166.6, 176.3, 176.5; 31P NMR (121.5 
MHz, CDCl3) δ: 12.4, 12.6; HRMS (ES+): calcd for C12H18N2O8P (M + H)+ 349.0801, found 





This was prepared following the general procedure for full deprotection, starting from (−)-(1S,4R)-18a 
(98% ee) (187 mg, 0.48 mmol) and TMSBr (371 mg, 0.32 mL, 2.42 mmol), in CH2Cl2 (20 mL), stirred 
overnight followed by water (0.3 mL) and NaOH (1M, 5 mL, ~5.0 mmol, 10 eq.) overnight at 50 °C. 
Purification by charcoal chromatography gave (+)-(1S,4R)-11 as the ammonium salt (81 mg, 46%, 
98% ee, dr 1:1). mp 225–227 °C; νmax/cm−1 (KBr) 3204 (NH), 3025 (CH), 1691 (C=O), 1588 (C=C), 
1433 (CH), 1273 (P=O), 1157 (C-N), 1057 (C-O); 1H NMR (300 MHz, D2O) δ: 1.65–2.17 (m, 5H), 
1.93 (s, 3H), 2.36–2.50 (m, 1H), 4.04–4.21 (m, 2H), 4.87–5.05 (m, 1H), 7.89 (br s, 1H). The 
enantiopurity of (+)-(1S,4R)-11a was assigned on the basis of the enantiopurities of the acetoxy 
alcohol (+)-(1R,4S)-15 and of the saturated product (−)-(1S,4R)-18a. 
 
(−)-(1R,4S)-1-{4-[Carboxy(phosphono)methoxy]cyclopentan-1-yl}thymine (−)-(1R,4S)-11a 
This was prepared following the general procedure for full deprotection, starting from (+)-(1R,4S)-18a 
(99% ee) (322 mg, 0.83 mmol) and TMSBr (632 mg, 0.55 mL, 4.13 mmol), in CH2Cl2 (55 mL) 
followed by water (0.5 mL) and NaOH (1M, 8.3 mL, ~ 8.3 mmol, 10 eq). Purification by charcoal 
column chromatography gave (−)-(1R,4S)-11a as the ammonium salt (151 mg, 50%, 99% ee, dr 1:1). 
mp 229–230 °C. [α]20D  – 2.67 (c = 0.52, H2O). The enantiopurity of (−)-(1R,4S)-11a was assigned on 
the basis of the enantiopurity of the acetoxy alcohol (−)-(1S,4R)-15. 
 
cis-1-{4-[Carboxy(phosphono)methoxy]cyclopentan-1-yl}uracil 11b 
This was prepared following the general procedure for full deprotection, starting from 18b (103 mg, 
0.27 mmol) and TMSBr (209 mg, 0.18 mL, 1.37 mmol) in CH2Cl2 (20 mL) at 0 °C, and stirred 
overnight at room temperature, followed by water (0.1 mL) and NaOH (1M, 5 mL, ~ 5.0 mmol, 18 eq.) 
and stirred at 50 °C. The crude residue was purified by charcoal chromatography to give 11b as the 
ammonium salt (55 mg, 58%, dr 1.1:1); νmax/cm−1 (KBr) 3201 (OH), 3052 (CH), 1686 (C=O), 1273 
(P=O), 1152 (C-O), 1062 (C-N); 1H NMR (600 MHz, D2O) δ: 1.51–1.60 (m, 0.5H), 1.60–177 (m, 
2.5H), 1.82–1.93 (m, 1H), 1.94–2.02 (m, 1H), 2.21–2.31 (m, 1H), 3.90 (d, JPC = 18.6, 0.5H), 3.91–4.03 
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(m, 1.5H), 4.80–4.88 (m, 1H), 5.74 (br d, J ≈ 7.8, 0.5H), 5.75 (br d, J ≈ 7.2, 0.5H), 7.99 (br d, J ≈ 7.8, 
1H); 13C NMR (150.9 MHz, D2O) δ: 29.5, 29.7, 31.1, 36.5, 37.7, 54.9, 55.1, 77.5 (br d, JPC ≈ 144.0)*, 
78.1 (br d, JPC ≈ 143.5)*, 80.0 (d, JPC = 11.3, 80.7 (d, JPC = 11.5), 102.1, 102.2, 145.35, 145.38, 152.6, 
152.7, 166.5, 176.4, 176.6; 31P NMR (161.9 MHz, CDCl3) δ: 12.17, 12.23; HRMS (ES+): calcd for 
C11H16N2O8P (M+H)+ 335.0644, found 335.0628; MS (ES+) m/z: 333 (M + H)+. 
 
(1S,4R)-1-{4-[Methoxycarbonyl(phosphono)methoxy]cyclopentan-1-yl}uracil (1S,4R)-19b 
This was prepared following the general procedure for partial deprotection, starting from (−)-(1S,4R)-
18b (98% ee) (147 mg, 0.39 mmol) and TMSBr (302 mg, 0.26 mL, 1.97 mmol) in CH2Cl2 (20 mL) 
overnight at room temperature, followed by water (0.2 mL), to give (1S,4R)-19b (131 mg, 96% yield, 
98% ee, dr 1:1). 1H NMR (300 MHz, D2O) δ: 1.49–2.11 (m, 5H), 2.22–2.38 (m, 1H), 3.68 (s, 1.5H), 
3.69 (s, 1.5H), 4.03–4.13 (m, 1H), 4.36 (d, JPC = 19.5, 0.5H), 4.40 (d, JPC = 19.5, 0.5H), 4.80–4.96 (m, 
1H [partially obscured by water]), 5.76 (d, J = 7.8, 1H), 7.90 (br d, J ~ 8.1, 0.5H), 7.95 (br d, J ~ 8.1, 
0.5H); 31P NMP (121.5 MHz, CDCl3) δ: 11.0, 11.2. 
 
(+)-(1S,4R)-1-{4-[Carboxy(phosphono)methoxy]cyclopentan-1-yl}uracil (+)-(1S,4R)-11b 
This was prepared from crude (+)-(1S,4R)-19b (98% ee) (131 mg, 0.38 mmol, isolated from the 
experiment above) in water (10 mL) and NaOH (1M, 5 mL, ~ 5 mmol, 18 eq), and stirring at 50 °C 
overnight. The crude residue was purified by charcoal chromatography to afford (+)-(1S,4R)-11b as 
the ammonium salt (63 mg, 48%, 98% ee, dr 1:1); [α]20D  + 8.30 (c 0.24, H2O). The enantiopurity of (+)-
(1S,4R)-11b was assigned on the basis of the enantiopurities of the acetoxy alcohol (+)-(1R,4S)-15, the 
phosphonucleoside (+)-(1R,4S)-17b and of the saturated product (−)-(1S,4R)-18b. 
 
(−)-(1R,4S)-1-{4-[Carboxy(phosphono)methoxy]cyclopentan-1-yl}uracil (−)-(1R,4S)-11b 
This was prepared following the general procedure for full deprotection, starting from (+)-(1R,4S)-18b 
(30% ee) (183 mg, 0.49 mmol) and TMSBr (348 mg, 0.30 mL, 2.27 mmol) in CH2Cl2 (20 mL) 
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overnight at room temperature, followed by water (0.2 mL) and NaOH (1M, 4.9 mL, ~ 4.90 mmol, 10 
eq.) at 50 °C overnight. The crude material was purified by charcoal chromatography to afford (−)-
(1R,4S)-11b as the ammonium salt (81 mg, 45%, 30% ee, dr 1.1:1); [α]20D  − 1.23 (c 0.29, H2O). The 
enantiopurity of (−)-(1R,4S)-11b was assigned on the basis of the enantiopurities of the acetoxy 




This was prepared following the general procedure for partial deprotection, starting from 18c (95 mg, 
0.25 mmol) and TMSBr (0.23 mL, 1.70 mmol, 7 eq) in CH2Cl2 (10 mL) at 40 °C for 8 h, followed by 
water (0.1 mL), to give 19c (88 mg, 99%, dr 1:1); 1H NMR (300 MHz, D2O) δ: 1.49–1.80 (m, 3H), 
1.80-1.97 (m, 1H,), 2.03–2.14 (m, 1H,), 2.19–2.31 (m, 1H), 3.65 (s, 2.6H), 4.00–4.12 (m, 1H), 4.33 (d, 
JPH = 19.2, 0.5H,), 4.37 (d, JPH = 19.5, 0.5H,), 4.83–5.02 (m, 1H), 6.06 (d, J = 7.8, 0.5H), 6.13 (d, J = 
7.8, 0.5H), 8.11 (d, J = 7.8, 0.5H), 8.16 (d, J = 8.1, 0.5H). Additional peak at 8.06 ppm (d, J = 8.1, 
0.1H) due to partial hydrolysis of the carboxyl ester. 
 
cis-1-{4-[Carboxy(phosphono)methoxy]cyclopentan-1-yl}cytosine 11c 
This was prepared from crude 19c (88 mg, 0.25 mmol isolated from the experiment above) in water 
(10 mL) and NaOH (1M, 2.5 mL, ~ 2.5 mmol, 10 eq), stirring at 40 °C for 28 h. The crude material 
was purified by charcoal chromatography to afford the fully deprotected phosphonate 11c (58 mg, 
66%, dr 1:1). mp > 250 °C; υmax/cm−1 (KBr): 3432 (br, NH), 2966 (CH), 1723 (C=O), 1650, 1595 
(C=C), 1490, 1399, 1286 (P=O), 1172 (C-N), 1087 (C-O); 1H NMR (600 MHz, D2O) δ: 1.52–1.60 (m, 
0.5H), 1.60–1.72 (m, 2.5H), 1.81–1.92 (m, 1H), 1.93–2.01 (m, 1H), 2.19–2.31 (m, 1H), 3.88 (d, JPH = 
18.0, 0.5H), 3.91–3.95 (m, 0.5H), 3.92 (d, JPH = 18.6, 0.5H), 3.96–4.00 (m, 0.5H), 4.82–4.90 (m, 1H), 
5.915 (d, J = 7.2, 0.5H), 5.923 (d, J = 7.8, 0.5H), 7.96 (d, J = 7.2, 0.5H), 7.97 (d, J = 7.2, 0.5H); 13C 
NMR (150 MHz, D2O) δ: 29.4, 30.0, 30.3, 31.1, 36.6, 37.9, 55.3, 55.6, 77.7 (d, JPC = 142.1,), 78.4 (d, 
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JPC = 141.4, 79.8 (d, JPC = 11.5), 80.5 (d, JPC = 11.8), 96.30, 96.34, 144.7, 144.8, 158.42, 158.45, 
165.35, 165.37, 176.8, 177.1; 31P NMR (121.5 MHz, D2O) δ: 11.3, 11.5; HRMS (ES+): calcd for 
C11H17N3O7P (M + H)+ 334.0804, found: 334.0802; MS (ES–) m/z: 332.0 (M – H)−. 
 
(+)-(1S,4R)-1-{4-[Carboxy(phosphono)methoxy]cyclopentan-1-yl}cytosine (+)-(1S,4R)-11c 
This was prepared following the general procedure for full deprotection, starting from (−)-(1S,4R)-18c 
(98% ee) (98 mg, 0.26 mmol) and TMSBr (0.18 mL, 1.4 mmol, 5 eq), in CH2Cl2 (15 mL), followed by 
NaOH (1M, 2.6 mL, ~ 2.6 mmol, 10 eq) at 50 °C for 18 h. The crude material was purified by charcoal 
chromatography and lyophilized to give (+)-(1S,4R)-11c as a fine cream solid (51 mg, 56% yield, 98% 
ee, dr 1.1:1); mp > 250 °C. 
 
(−)-(1R,4S)-1-{4-[Carboxy(phosphono)methoxy]cyclopentan-1-yl}cytosine (−)-(1R,4S)-11c 
This was prepared following the general procedure for full deprotection, starting from (+)-(1R,4S)-18c 
(70% ee) (67 mg, 0.18 mmol) and TMSBr (0.12 mL, 0.9 mmol, 5 eq) in CH2Cl2 (15 mL), followed by 
NaOH (1M, 1.8 mL, ~ 1.8 mmol, 10 eq) at 50 °C for 18 h. The crude material was purified by charcoal 
chromatography afford (−)-(1R,4S)-11c as a fine cream solid (26 mg, 41%, 70% ee, dr 1.1:1). mp > 
250 °C. The enantiopurity of (−)-(1R,4S)-11c was assigned on the basis of the enantiopurity of the 
acetoxy alcohol (−)-(1S,4R)-15. 
 
cis-9-{4-[Methoxycarbonyl(phosphono)methoxy]cyclopentan-1-yl}adenine 19d 
This was prepared following the general procedure for partial deprotection, starting from 18d (45 mg, 
0.11 mmol) and TMSBr (0.08 mL, 0.60 mmol) in CH2Cl2 (15 mL) at 40 °C for 9 h, followed by water 
(0.1 mL), to give 19d (38 mg, 93%, dr 1:1). 1H NMR (300 MHz, D2O) δ: 1.77–2.26 (m, 4H), 2.20–
2.37 (m, 1H), 2.41–2.55 (m, 1H), 3.67 (s, 1.5H), 3.70 (s, 1.5H), 4.16–4.27 (m, 1H), 4.37 (d, JPC = 18.9, 





This was prepared following the general procedure for full deprotection, starting from 18d (125 mg, 
0.31 mmol) and TMSBr (240 mg, 0.21 mL, 1.57 mmol) in CH2Cl2 (15 mL) under reflux for 7 h, 
followed by water (0.1 mL) and NaOH (1M, 3.1 mL, 3.10 mmol, 10 eq.) at 50 °C overnight. 
Purification by charcoal chromatography gave 11d as the ammonium salt (86 mg, 71%, dr 1.2:1). mp 
236–240 °C; νmax/cm−1 (KBr) 3342 (NH), 3198, 2961 (CH), 1603 (C=O), 1396, 1176 (C-N), 1071 (C-
O); 1H NMR (600 MHz, D2O) δ: 1.86–2.23 (m, 5H), 2.55–2.64 (m, 1H), 3.91 (d, JPC = 16.8, 0.55H), 
3.96 (d, JPC = 16.8, 0.45H), 4.09–4.17 (m, 1H), 4.75–4.83 (m [partially obscured by water], 1H), 8.11 
(s, 0.45H,), 8.12 (s, 0.55H), 8.45 (s, 0.45H), 8.50 (s, 0.55H); 13C NMR (150 MHz, D2O) δ: 29.3, 30.5, 
30.6, 30.7, 37.5, 38.6, 53.6, 53.8, 77.4 (d, JPC = 145.9), 78.1 (d, JPC = 148.8), 79.9 (d, JPC = 10.3), 80.5 
(d, JPC = 10.7), 117.8, 117.9, 141.11, 141.14, 148.2, 151.2, 154.5, 154.6, 176.6, 176.8; 31P NMR 
(121.5 MHz, D2O) δ: 11.7, 11.8; HRMS (ES+): calcd for C12H17N5O6P (M + H)+ 358.0916, found 




This was prepared following the general procedure for full deprotection, starting from (−)-(1S,4R)-18d 
(98% ee) (114 mg, 0.29 mmol) and TMSBr (218 mg, 0.19 mL, 1.43 mmol) in CH2Cl2 (15 mL), 
followed by water (0.1 mL) and NaOH (1M, 2.9 mL, ~2.90 mmol, 10 eq.) at 50 °C. The crude material 
was purified by charcoal chromatography to afford (+)-(1S,4R)-11d as the ammonium salt (88 mg, 
78%, 98% ee, dr 1.1:1). mp 234–239 °C; [α]20D  + 13.50 (c 0.2, CH2Cl2) The enantiopurity of (+)-
(1S,4R)-11d was assigned on the basis of the enantiopurities of the acetoxy alcohol (+)-(1R,4S)-15. 
 
(−)-(1R,4S)-9-{4-[Carboxy(phosphono)methoxy]cyclopentan-1-yl}adenine (−)-(1R,4S)-11d 
This was prepared following the general procedure for full deprotection, starting from (−)-(1R,4S)-18d 
(70% ee) (122 mg, 0.31 mmol) and TMSBr (239 mg, 0.21 mL, 1.55 mmol) in CH2Cl2 (15 mL) at 40 
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°C for 9 h, followed by water (0.1 mL) and NaOH (1M, 3.0 mL, ~ 3.0 mmol, 10 eq.) overnight at 50 
°C. The crude material was purified by charcoal chromatography to afford (−)-(1R,4S)-11d as the 
ammonium salt (59 mg, 59%, 70% ee, dr 1.1:1). mp 237–241 °C; [α]20D  – 6.70 (c 1.00, CH2Cl2). The 





This was prepared following the general procedure for full deprotection, starting from 18f (51 mg, 
0.129 mmol) and TMSBr (79 mg, 67 µL, 0.517 mmol) in acetonitrile (3 mL) and irradiated (50W, 50 
°C) for 10 min, followed by 50% aq. MeOH (0.2 mL) and LiOH (31 mg, 1.29 mmol) in water (3 mL) 
2h at 50 °C. The crude material was purified by charcoal chromatography to afford 11f as the 
ammonium salt (25 mg, 52%). mp 243 °C; 1H NMR (300 MHz, D2O) δ: 1.69–2.17 (m, 5H), 2.40–2.51 
(m, 1H), 3.99-4.14 (m, 2H), 4.93-5.01 (m, 1H), 8.33 (d, J = 8.4, 0.5H), 8.35 (d, J = 8.8, 0.5H); 13C 
NMR (150 MHz, D2O) δ: 29.3, 29.35, 29.4, 36.6, 37.5, 55.4, 55.6, 78.4 (d, J = 139.8), 78.9 (d, J = 
139.3), 79.7 (d, J = 10.6), 80.3 (d, J = 10.2), 128.7, 128.9, 140.2, 141.7, 152.0, 160.5, 160.7, 177.6, 
178.0; 31P NMR (121.5 MHz, D2O) δ: 12.09, 12.32; 19F NMR (282.4 MHz, D2O) δ: − 165.89, − 
165.86; HRMS (ES+) calcd for C11H15FN2O8P (M + H)+ 353.0550, found 353.0535; calcd for 
C11H14DFN2O8P (M + H)+ 354.0613, found 354.0597; MS (ES–) m/z: 351.2 (M – H)–. Some indication 
of D-exchange visible in 1H and 19F NMR spectra. 
 
Unsaturated and oxygenated derivatives 
cis-1-{4-[(Methoxycarbonyl)phosphonomethoxy]cyclopent-2-en-1-yl}thymine 20a 
A solution of 17a (0.23 g, 0.6 mmol) and 2,6-lutidine (284 µL, 0.26 g, 2.4 mmol) in acetonitrile (3 
mL), was treated with TMSBr (325 µL, 0.38 g, 2.4 mmol), and the resulting mixture was irradiated 
(50W, 50 °C) for 10 min. The reaction was quenched by the addition of MeOH/H2O (95:5), and the 
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mixture concentrated under reduced pressure. The residue was purified by charcoal chromatography to 
provide an amber glass (0.21 g) which was crystallized from methanol/ether to afford 20a as a cream 
solid (0.17 g, 78%). mp 198–205 °C; 1H NMR (400 MHz, D2O) δ: 1.51–1.64 (m, 1H), 1.76 (s, 3H), 
2.69–2.86 (m, 1H), 3.64 (s, 1.5H), 3.68 (s, 1.5H), 4.28 (d, JPH = 18.5, 0.5H), 4.29 (d, JPH = 17.9, 0.5H), 
4.52–4.59 (m, 0.5H), 4.59–4.66 (m, 0.5H), 5.28–5.40 (m, 1H), 5.79–5.89 (m, 1H), 6.13–6.30 (m, 1H,), 
7.39 (s, 0.5H), 7.44 (s, 0.5H); 13C NMR (150 MHz, CD3OD) δ: 12.4, 37.8, 37.9, 52.5, 59.6, 59.8, 78.7 
(d, JPC = 140.3), 79.0 (d, JPC = 141.8), 85.2 (d, JPC = 10.6), 85.4 (d, JPC = 9.0), 111.9, 112.0, 134.1, 
134.4, 138.0, 139.9, 140.0, 152.9, 153.0, 166.6, 166.7, 172.8, 173.0; 31P NMR (202 MHz, CD3OD) δ: 
8.6, br; HRMS (ES+) calcd for C13H18N2O8P (M + H)+ 361.0801, found 361.0795; MS (ES+) m/z: 
383.3 (M + Na)+ 
 
cis-1-{4-[(Carboxyl)phosphonomethoxy]cyclopent-2-en-1-yl}thymine 12a 
A solution of 20a (113 mg, 0.3 mmol) and LiOH (63 mg, 2.6 mmol) in water (2.5 mL was stirred at 60 
°C for 4.25 h. The mixture was concentrated and purified by charcoal chromatography to afford 12a as 
a white solid (84 mg, 78%). mp 236–239 °C; 1H NMR (400 MHz, D2O) δ: 1.50–1.68 (m, 1H), 1.76 (s, 
3H), 2.67–2.90 (m, 1H), 3.78–4.10 (m, 1H), 4.44–4.66 (m, 1H), 5.27–5.38 (m, 1H), 5.72–5.82 (m, 1H), 
6.14–6.33 (m, 1H), 7.44 (s, 0.5H), 7.46 (s, 0.5H); 13C NMR (150 MHz, D2O) δ: 11.3, 36.6, 36.8, 58.9, 
59.0, 78.4 (br), 83.4, 111.3, 132.1, 132.2, 136.7, 137.2, 139.8, 139.9, 152.3, 166.8, 177.1; 31P NMR 
(202 MHz, D2O) δ: 12.3 br; HRMS (ES+) calcd for C12H16N2O8P (M + H)+ 347.0644, found 347.0653; 
MS (ES+) m/z: 347.3 (M + H)+. 
 
2-((4-(5-Fluoro-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)cyclopent-2-en-1-yl)oxy)-2-
phosphonoacetic acid 12f 
A solution of 17f (94 mg, 0.240 mmol) and 2,6-lutidine (103 mg, 112 µL, 0.960 mmol) in acetonitrile 
(3 mL) was treated with TMSBr (147 mg, 124 µL, 0.960 mmol). The resulting solution was irradiated 
(50W, 50°C) for 10 min. Water (0.3 mL) and methanol (0.3 mL) were added and the mixture was 
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stirred 20 min at room temperature. The mixture was concentrated and the residue was stirred with 
lithium hydroxide (57 mg, 2.40 mmol) in water (5 mL) for 1h at 50°C, then concentrated again. The 
crude material was purified by charcoal chromatography to afford 12f as the ammonium salt (71 mg, 
0.193 mmol, 81%, 1 : 1 dr). 1H NMR (300 MHz, D2O) δ: 1.74–1.82 (m, 1H), 2.87–2.97 (m, 1H), 4.14 
(d, J = 18.5, 0.50H), 4.17 (d, J = 17.9, 0.5H), 4.66–4.78 (m, 1H), 5.49–5.55 (m, 1H), 5.96–6.00 (m, 
1H), 6.40 (d, J = 5.6, 0.5H), 6.46 (d, J = 5.5, 0.5H), 7.98 (d, J = 6.5, 0.5H), 7.99 (d, J = 6.4,0.5H); 13C 
NMR (75.5 MHz, D2O) δ: 36.2, 36.5, 59.76, 59.85, 78.6 (d, J = 133.6), 83.2 (d, J = 13.2), 128.1 (d, J = 
33.5), 128.2 (d, J = 33.4), 132.0, 132.1, 137.3, 137.8, 140.9 (d, J = 232.2), 150.9, 159.8 (d, J = 25.4), 
176.9; 31P NMR (121.5 MHz, D2O) δ: 12.08, 12.31; 19F NMR (282.4 MHz, D2O) δ: − 166.20, − 
166.16; HRMS (ES+) calcd for C11H13FN2O8P (M + H)+ 351.0394, found 351.0407; MS (ES–) m/z: 
349.2 (M – H). 
 
Non phosphonate compounds 
Benzyl 2-((4-acetoxycyclopent-2-en-1-yl)oxy)acetate 21 
The allylic acetate 14 (350 mg, 2.46 mmol) was dissolved in benzene (20 mL) and purged with 
nitrogen. Rhodium acetate (20 mg) was added and the mixture stirred for 5 min at room temperature. 
Benzyl diazoacetate (800 mg, 4.54 mmol) was added and the reaction was refluxed overnight. The 
reaction mixture cooled to room temperature, filtered and the solvent removed under vacuum to afford 
a green residue which was purified by chromatography (SiO2, 25% ethyl acetate/hexane) to give the 
desired product 21 as a clear oil (0.14 g, 19%).1H NMR (300 MHz, CDCl3) δ: 1.71–1.79 (m, 1H), 2.00 
(s, 3H), 2.71–2.81 (m, 1H), 4.14 (s,2H), 4.52–4.56 (m, 1H), 5.19 (s, 2H), 5.49–5.56 (m, 1H), 5.99–6.08 
(m, 1H), 6.12–6.17 (m, 1H), 7.31–7.39 (m, 5H); 13C NMR (75.5 MHz, CDCl3) δ: 21.1, 37.0, 66.0, 
66.6, 76.5, 82.6, 128.4, 128.5, 128.6, 133.7, 135.4, 135.5, 170.3, 170.8; HRMS (ES+): calcd for 






A microwave vial containing a degassed suspension of thymine (63 mg, 0.50 mmol) and sodium 
carbonate (38 mg, 0.35 mmol) in water (1 mL) and acetonitrile (1 mL) was heated under microwave 
conditions (50°C, 200 W) for 30 min. A degassed solution of 21 (140 mg, 0.48 mmol) in acetonitrile (1 
mL), Pd(dba)2 (10 mg, 4 mol%) and 1,4-bis(diphenylphosphino)butane (dppb) (14 mg, 7 mol%) was 
added to the vial. The resulting solution was irradiated (50°C, 200 W) for 30 min whereupon a second 
portion of Pd(dba)2 (10 mg) and dppb (14 mg) was added followed by irradiation (50°C, 200 W) for a 
further 30 min. The reaction mixture was cooled to room temperature, gravity filtered and concentrated 
under vacuum to give a purple residue which was purified by chromatography (SiO2, 5% 
methanol/dichloromethane) to afford compound 22 as an oil (36 mg, 21%).1H NMR (300 MHz, 
CDCl3) δ: 1.66–1.73 (m, 1H), 1.88 (s, 3H), 2.76–2.86 (m, 1H), 4.21 (s,2H), 4.52–4.55 (m, 1H), 5.21 (s, 
2H), 5.61-5.66 (m, 1H), 5.86–5.89 (m, 1H), 6.28–6.31 (m, 1H), 7.21 (s, 1H), 7.33–7.38 (m, 5H), 9.01 
(bs, 1H); 13C NMR (75.5 MHz, CDCl3) δ: 12.4. 37.3, 57.9, 66.8, 67.1, 83.2, 111.5, 128.5, 128.6, 128.7, 
133.5, 135.2, 136.5, 137.1, 151.1, 163.9, 170.0; HRMS (ES+): calcd for C19H21N2O5 (M+H)+ 
357.1450, found 357.1436; MS (ES+) m/z: 357 (M + H)+. 
 
2-((3-(5-Methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)cyclopentyl)oxy)acetic acid 23 
The base insertion product 22 (36 mg, 0.10 mmol) was dissolved in methanol (2 mL) and flushed with 
nitrogen. Palladium on carbon 10% (10 mg) was added and the suspension stirred under a hydrogen 
filled balloon at room temperature for 18 h. The reaction mixture was filtered through a pad of Celite®, 
and concentrated under vacuum to give the title product 23 as a colorless solid (22 mg, 82%).1H NMR 
(300 MHz, CD3OD) δ: 1.62–1.75 (m, 1H), 1.79–1.89 (m, 2H), 1.91 (s, 3H), 2.06–2.21 (m, 2H), 2.31–
2.41 (m, 1H), 4.04–4.14 (m, 3H), 5.09–5.20 (m, 1H), 7.89 (s, 1H); 13C NMR (75.5 MHz, CD3OD) δ: 
10.9, 29.5, 30.5, 37.4, 53.8, 65.3, 80.2, 110.6, 139.0,151.8, 165.0, 172.7; HRMS (ES+): calcd for 







A suspension of 17a (45 mg, 0.12 mmol) in THF (3 mL) was treated with 4% aq. osmium tetroxide 
(810 µL, 810 mg, 0.13 mmol). The resulting solution was stirred for 24 hours then quenched with 5% 
Na2S2O5, concentrated under reduced pressure and purified by flash chromatography (10% 
MeOH/CH2Cl2) to afford the desired product 24 as a white solid (26 mg, 53%). 1H NMR (400 MHz, 
CDCl3) δ: 1.67–1.82 (m, 1H), 1.90 (s, 1.5H), 1.92 (s, 1.5H), 2.53–2.82 (m, 1H), 3.76–3.92 (m, 9H), 
3.94–4.09 (m, 1H), 4.12–4.27 (m, 1H), 4.29–4.41 (m, 1H), 4.43–4.76 (m, 1H), 4.62 (d, JPH = 19.1, 
0.5H), 4.72 (d, JPH = 20.0, 0.5H), 4.86–5.12 (m, 2H), 7.46 (s, 0.5H), 7.53 (s, 0.5H), 10.33 (br s, 0.5H), 
10.36 (br s, 0.5H); 13C NMR (150 MHz, CDCl3) δ: 12.2, 12.3, 33.2, 33.5, 53.1, 54.1–54.6 (m), 59.2, 
59.3, 74.1, 74.4, 74.5 (d, JPC = 159.8), 74.6 (d, JPC = 158.6), 76.5, 76.6, 84.1–84.4 (m), 111.7, 111.9, 
138.1, 138.2, 152.2, 152.3, 164.4, 167.6 (d, J = 1.6), 167.7 (d, J = 2.0); 31P NMR (202 MHz, CDCl3) δ: 
16.82, 16.84; HRMS (ES+) calcd for C15H24N2O10P (M + H)+ 423.1169, found 423.1165; MS (ES+) 
m/z: 423.3 (M + H)+. 
 
cis-1-{4-[(Carboxyl)phosphonomethoxy]-2,3-dihydroxycyclopentan-1-yl}thymine 13 
A 10 mL microwave tube was charged with 24 (23 mg, 0.05 mmol), TMSBr (28 µL, 32 mg, 2.3 mmol) 
and acetonitrile (2 mL) and the mixture was irradiated at 50 °C for 10 minutes. Thereafter, the reaction 
was quenched with MeOH-H2O (95:5) and the mixture concentrated under reduced pressure. The 
residue was dissolved in water (2 mL), lithium hydroxide (7 mg, 3 mmol) was added and the solution 
was stirred at 60 °C for 3.5 hours. After concentration under reduced pressure and acidification, the 
residue was purified by charcoal chromatography to afford the desired product 13 as a white solid (14 
mg, 65 %). 1H NMR (300 MHz, D2O) δ: 1.67–1.83 (m, 1H), 1.87 (s, 3H), 2.50–2.69 (m, 1H), 3.70–
3.93 (m, 1H), 3.93–4.25 (m, 2H), 4.30–4.48 (m, 1H), 4.76–4.95 (m, 1H), 7.70 (s, 0.5H), 7.71 (s, 0.5H); 
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31P NMR (121 MHz, D2O) δ: 11.98; HRMS (ES+) calcd for C12H18N2O10P (M + H)+ 381.0699, found 




A mixture of 17a (39 mg, 0.1 mmol), benzonitrile (258µL, 258 mg, 2.5 mmol) and potassium 
carbonate ( 14 mg, 0.1 mmol) in methanol (3 mL) was treated dropwise over 10 minutes with 30% aq. 
hydrogen peroxide (256µL, 285 mg, 2.5 mmol). Thereafter, the reaction mixture was stirred for 3 
hours, quenched with water and extracted with CH2Cl2 (3 × 30 mL). The combined organic extracts 
were dried over MgSO4 and concentrated and the residue was purified by flash chromatography (5% 
MeOH/CH2Cl2) to afford the desired epoxide 25 as a white solid (10 mg, 25%). 1H NMR (400 MHz, 
CDCl3) δ: 1.45–1.60 (m, 1H), 1.95 (s, 1.5H), 1.96 (s, 1.5H), 2.31–2.42 (m, 1H), 3.60-3.63 (m, 1H), 
3.73–3.77 (m, 1H), 3.80–3.93 (m, 9H), 4.17–4.28 (m, 1H), 4.50 (d, JPH = 18.8, 0.5H), 4.59 (d, JPH = 
19.2, 0.5H), 4.90–4.98 (m, 1H), 7.49–7.55 (m, 1H), 8.08 (s, 1H); 13C NMR (150 MHz, CDCl3) δ: 12.5, 
12.6, 27.8, 27.9, 51.9, 52.0, 53.16, 53.18, 53.90, 54.3–54.5 (m), 74.8 (d, JPC = 158.5), 75.1 (d, JPC = 
159.3), 78.8 (d, JPC = 11.2), 78.9 (d, JPC = 10.8), 111.9, 112.0, 129.7, 136.7, 136.8, 150.6, 163.2, 167.5; 
31P NMR (202 MHz, CDCl3) δ: 15.7,15.8; HRMS (ES+) calcd for C15H22N2O9P (M + H)+ 405.1063, 
found 405.1049; MS (ES+) m/z: 405.2 [M + H]+. 
 
Antiviral Activity Assays 
The compounds were evaluated against the following viruses: herpes simplex virus type 1 (HSV-1) 
strain KOS, thymidine kinase-deficient (TK-) HSV-1 strain KOS resistant to ACV (ACVr), herpes 
simplex virus type 2 (HSV-2) strain G, vaccinia virus Lederle strain, respiratory syncytial virus (RSV) 
strain Long, vesicular stomatitis virus (VSV), Coxsackie B4, Parainfluenza 3, Influenza virus A 
(subtypes H1N1, H3N2), influenza virus B, Reovirus-1, Sindbis, Reovirus-1, Punta Toro, human 
immunodeficiency virus type 1 (HIV-1) strain IIIB and human immunodeficiency virus type 2 (HIV-2) 
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strain ROD. The antiviral, other than anti-HIV, assays were based on inhibition of virus-induced 
cytopathicity in human embryonic lung (HEL) fibroblasts, African green monkey cells (Vero), human 
epithelial cells (HeLa) or Madin-Darby canine kidney cells (MDCK). Confluent cell cultures in 
microtiter 96-well plates were inoculated with 100 CCID50 of virus (1 CCID50 being the virus dose to 
infect 50% of the cell cultures) in the presence of varying concentrations of the test compounds. Viral 
cytopathicity was recorded as soon as it reached completion in the control virus-infected cell cultures 
that were not treated with the test compounds. Antiviral activity was expressed as the EC50 or 
compound concentration required to reduce virus-induced cytopathicity by 50%. 
 
Anti-HIV Activity Assays  
Inhibition of HIV-1(IIIB)- and HIV-2(ROD)-induced cytopathicity in CEM cell cultures was measured 
in microtiter 96-well plates containing 3 × 105 CEM cells/mL infected with 100 CCID50 of HIV per 
milliliter and containing appropriate dilutions of the test compounds. After 4−5 days of incubation at 
37 °C in a CO2-controlled humidified atmosphere, CEM giant (syncytium) cell formation was 
examined microscopically. The EC50 (50% effective concentration) was defined as the compound 
concentration required to inhibit HIV-induced giant cell formation by 50%. 
 
HIV-1 RT Assays 
To prepare the template/primers for the RT experiments, 0.15 mM poly(U), poly(A), and poly(I) were 
mixed with an equal volume of 0.0375 mM oligo(dA), oligo(dT), and oligo(dC), respectively. The 
final concentrations of the templates in the RT reaction mixture were 0.015 mM. The reaction mixture 
(50 µl) contained 50 mM Tris.HCl (pH 7.8), 5 mM dithiothreitol, 300 mM glutathione, 500 µM 
EDTA, 150 mM KCl, 5 mM MgCl2, 1.25 µg of bovine serum albumin, an appropriate concentration of 
labeled (tritiated) substrate dTTP, dCTP, or dATP (2 µCi/assay), a fixed concentration of the 
template/primer poly(A).oligo(dT) (0.015 mM), poly(I).oligo(dC) (0.015 mM), and poly(U).oligo(dA) 
(0.015 mM), 0.06% Triton X-100, 10 µl of inhibitor solution (containing various concentrations of the 
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compounds), and 1 µl of the RT preparation. The reaction mixtures were incubated at 37°C for 30 min, 
at which time 100 µl of yeast RNA (1 mg/ml) and 1 ml of Na4P2O7 (0.02 M) in trichloroacetic acid 
(5% v/v) were added. The solutions were kept on ice for 30 min, after which the acid-insoluble 
material was washed and analyzed for radioactivity. The 50% inhibitory concentration (IC50) of the 
test compounds was determined in the presence of fixed concentrations of 1.25 µM [3H]dTTP, 1.75 
µM [3H]dATP, or 2.5 µM [3H]dCTP. 
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